WO2004106304A2 - 3 - [2- (3-amino-2-oxo-2h-pyridin-1-yl) - acetylamino] - 4- oxo-pentanoic acid derivatives and their use as caspase inhibitors - Google Patents

3 - [2- (3-amino-2-oxo-2h-pyridin-1-yl) - acetylamino] - 4- oxo-pentanoic acid derivatives and their use as caspase inhibitors Download PDF

Info

Publication number
WO2004106304A2
WO2004106304A2 PCT/US2004/016706 US2004016706W WO2004106304A2 WO 2004106304 A2 WO2004106304 A2 WO 2004106304A2 US 2004016706 W US2004016706 W US 2004016706W WO 2004106304 A2 WO2004106304 A2 WO 2004106304A2
Authority
WO
WIPO (PCT)
Prior art keywords
aliphatic
aryl
heteroaryl
heterocyclyl
cycloaliphatic
Prior art date
Application number
PCT/US2004/016706
Other languages
French (fr)
Other versions
WO2004106304A3 (en
Inventor
Guy Brenchley
Jean-Damien Charrier
Steven Durrant
Ronald Knegtel
Michael Mortimore
John R. Studley
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA05012837A priority Critical patent/MXPA05012837A/en
Priority to NZ544156A priority patent/NZ544156A/en
Priority to AU2004243308A priority patent/AU2004243308B9/en
Priority to CA002526749A priority patent/CA2526749A1/en
Priority to EP04753524A priority patent/EP1631549A2/en
Priority to BRPI0410669-5A priority patent/BRPI0410669A/en
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to JP2006533446A priority patent/JP4791365B2/en
Priority to CN2004800181618A priority patent/CN1812972B/en
Publication of WO2004106304A2 publication Critical patent/WO2004106304A2/en
Publication of WO2004106304A3 publication Critical patent/WO2004106304A3/en
Priority to IL172159A priority patent/IL172159A/en
Priority to NO20056192A priority patent/NO20056192L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit caspases that mediate cell apoptosis and inflammation.
  • the invention also 'relates to processes for preparing these compounds.
  • the invention further relates .to methods of using the compounds and pharmaceutical compositions of this invention to treat diseases where caspase activity is implicated.
  • Apoptosis or programmed cell death, is a principal mechanism by which organisms eliminate unwanted cells.
  • Caspases are a family of cysteine protease enzymes that are key mediators in the signaling pathways for apoptosis and cell disassembly (Thornberry, Chem. Biol .
  • Caspases are involved in both the effector phase of the signaling pathway and further upstream at its initiation. The upstream caspases involved in initiation events become activated and in turn activate other caspases that are involved in the later phases of apoptosis.
  • Caspase-1 the first identified caspase, is also known as interleukin converting enzyme or "ICE.”
  • Caspase-1 converts precursor interleukin-l ⁇ ("pIL-l ⁇ ”) to the pro-inflammatory active form by specific cleavage of pIL-l ⁇ between Asp-116 and Ala-117.
  • caspase-1 there are also eleven other known human caspases, all of which cleave specifically at aspartyl residues. They are also observed to have stringent requirements for at least four amino acid residues on the N-terminal side of the cleavage site.
  • the caspases have been classified into three groups depending on the amino acid sequence that is preferred or primarily recognized.
  • caspases which includes caspases 1, 4, 5 and 13, have been shown to prefer hydrophobic aromatic amino acids at position 4 on the N-terminal side of the cleavage site.
  • Another group which includes caspases 2, 3 and 7, recognize aspartyl residues at both positions 1 and 4 on the N-terminal side of the cleavage site, and preferably a sequence of Asp-Glu-X-Asp.
  • a third group which includes caspases 6, 8, 9 and 10, tolerate many amino acids in the primary recognition sequence, but seem to prefer residues with branched, aliphatic side chains such as valine and leucine at position 4.
  • the caspases have also been grouped according to their perceived function.
  • the first subfamily consists of caspases-1 (ICE), 4, 5 and 13. These caspases have been shown to be involved in pro- inflammatory cytokine processing and therefore play an important role in inflammation.
  • Caspase-1 the most studied enzyme of this class, activates the IL-l ⁇ precursor by proteolytic cleavage. This enzyme therefore plays a key role in the inflammatory response.
  • Caspase-1 is also involved in the processing of interferon- ⁇ inducing factor (IGIF, also known as IL-18) which stimulates the production of interferon gamma, a key immunoregulator that modulates antigen presentation, T- cell activation and cell adhesion. [0007] The remaining caspases make up the second and third subfamilies.
  • IGIF interferon- ⁇ inducing factor
  • One subfamily consists of the enzymes involved in initiating events in the apo otic pathway, including transduction of signals from the plasma membrane. Members of this subfamily include caspases-2, 8, 9 and 10. The other subfamily, consisting of the effector capsases 3, 6 and 7, are involved in the final downstream cleavage events that result in the systematic breakdown and death of the cell by apoptosis. Caspases involved in the upstream signal transduction activate the downstream caspases, which then disable DNA repair mechanisms, fragment DNA, dismantle the cell cytoskeleton and finally fragment the cell .
  • R is an acyloxymethylketone -COCH 2 OCOR' .
  • R' is exemplified by an optionally substituted phenyl such as 2, 6-dichlorobenzoyloxy and where R is C0CH 2 X where X is a leaving group such as F or Cl .
  • caspase inhibitors to treat a variety of mammalian disease states associated with an increase in cellular apoptosis has been demonstrated using peptidic caspase inhibitors.
  • caspase inhibitors have been shown to reduce infarct size and inhibit cardiomyocyte apoptosis after myocardial infarction, to reduce lesion volume and neurological deficit resulting from stroke, to reduce post-traumatic apoptosis and neurological deficit in traumatic brain injury, to be effective in treating fulminant liver destruction, and to improved survival after endotoxic shock.
  • peptidic inhibitors described above are very potent against some of the caspase enzymes. However, this potency has not always been reflected in cellular models of apoptosis .
  • peptide inhibitors are typically characterized by undesirable pharmacological properties such as poor oral absorption, poor stability and rapid metabolism. Plattner and Norbeck, in Drug Discovery Technologies, Clark and Moos, Eds. (Ellis Horwood, Chichester, England, 1990) .
  • the present invention also provides pharmaceutical compositions comprising a compound of formula I and methods using such compounds and compositions for treating caspase-mediated diseases.
  • the present invention also provides processes for preparing the compounds of formula I .
  • R 1 is R 5 C(0)-, HC(O)-, R 6 S0 2 -, R 6 OC(0)-, (R 6 ) 2 NC(0)-,
  • R 2 is hydrogen, -CF 3 , halo, -OR 7 , -N0 2 , -OCF 3 , -CN, or R 8 ;
  • R 3 is hydrogen or (C1-C4) -aliphatic-;
  • R 4 is -COOH or -C00R 8 ;
  • R 5 is -CH 2 F or -CH 2 0-2 , 3 , 5 , 6-tetraf luorophenyl ;
  • R 5 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- CIO) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10)- heteroaryl (C1-C12) -aliphatic-, or two R 6 groups bound to the same atom form together with that atom a 3- to lO-membered aromatic or nonaromatic ring
  • heterocyclyl wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R) , S, SO, and S0 2 ; and wherein R 5 is substituted with up to 6 substituents independently selected from R;
  • the present invention also provides a compound of formula I:
  • R 1 is R 6 C(0) R 6 S0 2 -, R 6 0C(0) (R 6 ) 2 NC(0)-, R 6 C(0)C(0)-,
  • R is hydrogen, -CF 3 , halo, -OR , -N0 2 , -OCF 3 , -CN, or R 8 ;
  • R 3 is hydrogen or (C1-C4) -aliphatic-;
  • R 4 is -COOH or -COOR 8 ;
  • R 5 is -CH 2 F or -CH 2 0-2 , 3 , 5 , 6-tetrafluorophenyl;
  • R 6 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- Cl0)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10) - heteroaryl (C1-C12) -aliphatic-, or two R 6 groups bound to the same atom form together with that atom a 3- to 10-membered aromatic or nonaromatic ring; wherein the ring is optionally fused to a (C6-C10) aryl, (C5- C10) heteroaryl, (C3-C10) cycl
  • R is halogen, -OR 7 , -OC (0)N(R 7 ) 2 , -N0 2 , -CN, -CF 3 , -OCF 3 , -R 7 , oxo, thioxo, 1, 2-methylenedioxy, 1,2- ethylenedioxy, -N(R 7 ) 2 , -SR 7 , -SOR 7 , -S0 2 R 7 , -S0 2 N(R 7 ) 2 , -SO 3 R 7 , -C(0)R 7 , -C(0)C(0)R 7 , -C(0)CH 2 C(0)R 7 , -C(S)R 7 , -C(0)OR 7 , -OC(0)R 7 , -C(0)N(R 7 ) 2 , -OC (O)N(R 7 ) 2 , -C(S)N(R 7 ) 2 , -(CH 2 ) 0 - 2 NHC(O)R
  • J 2 is halogen, -OR 7 , -OC (O)N(R 7 ) 2 , -N0 2 , -CN, -CF 3 , -OCF 3 , -R 7 , oxo, thioxo, 1, 2-methylenedioxy, 1,2- ethy1enedioxy, -N(R 7 ) 2 , -SR 7 , -SOR 7 , -S0 2 R 7 , -S0 2 N(R 7 ) 2 , -S0 3 R 7 , -C(0)R 7 , -C(0)C(0)R 7 , -C(0)CH 2 C(0)R 7 , -C(S)R 7 , -C(0)OR 7 , -OC(0)R 7 , -C(0)N(R 7 ) 2 , -OC (O)N(R 7 ) 2 , -C(S)N(R 7 ) 2 , -(CH 2 ) 0 - 2
  • R 8 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- CIO) -heterocyclyl- (C1-C12) -aliphatic-, or (C5-C10)- heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N(H) , N(R) , S, SO, and S0 2 .
  • R 1 is R 6 C(0)-, R 6 S0 2 -, or R 6 -.
  • R ⁇ is R 6 C(0)-.
  • R 1 is R 6 S0 2 -.
  • R 1 is R 6 -.
  • R 1 is (R 6 ) 2 NC(0)- or (R 6 )0C(0)-.
  • R 1 is (R 6 ) 2 NC(0)-.
  • R 1 is (R 6 ) (H)NC (0) - .
  • R 1 is (R 5 )0C(0)-.
  • each R 6 is independently (C1-C4) -aliphatic-, (C3-C10)- cycloaliphatic, (C3-CIO) -heterocyclyl, (C5-C10)- heteroaryl, (C6-C10) -aryl-, or (C6-C10) -aryl- (C1-C12) - (it being understood that optionally up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R) , S, SO, and S0 2 ; and wherein R 6 is optionally substituted with up to 6 substituents independently selected from R or R 6 is substituted as disclosed in any of the embodiments herein) .
  • each R 6 is independently H, (C1-C4) -aliphatic- or (C6-C10) -aryl- or each R 6 together with the N-atom is a (C3-C7) -cycloaliphatic.
  • each R 6 is independently (C1-C4) -aliphatic-, (C5-C10) -heteroaryl-, or (C6-C10)- aryl-, wherein the heteroaryl or aryl is optionally substituted or wherein each R 6 together with the N-atom is a (C3-C7) -cycloaliphatic group.
  • each R 6 is independently (C1-C4) -aliphatic- or (C6-C10) -aryl-, wherein the aryl is optionally substituted or wherein each R s together with the N-atom is a (C3-C7) -cycloaliphatic.
  • each R 6 is independently (C1-C4) -aliphatic-, (C3-C7) -cycloaliphatic, (C6-C10) -aryl-, (C5-C10) -heteroaryl, wherein the heteroaryl and aryl are independently and optionally substituted, or each R 6 together with the N-atom is a (C3-C7) -cycloaliphatic.
  • R 2 is hydrogen, C1-, C2-, C3-, or C4-alkyl-,
  • R 2 is hydrogen, Cl-alkyl-, C2-alkyl-, or CF 3 . More preferably, R 2 is hydrogen or CF3. [0025] According to another preferred embodiment, R 3 is •ethyl .
  • R 5 is -CH 2 0-2 ,3,5, 6-tetrafluorophenyl .
  • R 5 is -CH 2 F.
  • R 8 is (C1-C12) -alkyl. More preferably, R 8 is (C1-C4) -alkyl .
  • each R and J 2 are independently halogen, -OR 7 , -OC (O) (R 7 ) 2 , -N0 2 , -CN, -CF 3 , -OCF 3 , -R 7 , ox ⁇ , 1,2-methylenedioxy, 1,2- ethylenedioxy, -N(R 7 ) 2 , -C(0)R 7 , -C(0)C(0)R 7 , -C(0)OR 7 , -OC(0)R 7 , -C(0)N(R 7 ) 2 , or -OC (O)N(R 7 ) 2 .
  • the carbon atom designations may have the indicated integer and any intervening integer.
  • the number of carbon atoms in a (C1-C4) -alkyl group is 1, 2, 3, or 4. It should be understood that these designation refer to the total number of atoms in the appropriate group.
  • the total number of carbon atoms and heteroatoms is 3 (as in aziridine) , 4, 5, 6 (as in morpholine) , 7, 8, 9, or 10.
  • an aliphatic group includes straight-chained and branched groups having the specified number of atoms. If the number of atoms is unspecified, the aliphatic group has from 1 to 12 carbon atoms . As would be understood, alkenyl and/or alkynyl aliphatic groups have a minimum of 2 carbon atoms . Preferred aliphatic groups are alkyl groups (preferably having from 1 to 6 atoms) .
  • preferred aliphatic groups of this invention are alkyl groups and have 1, 2, 3, 4, 5, or 6 carbon atoms . More preferred alkyl groups have 1, 2, 3, or 4 carbon atoms.
  • Preferred alkenyl and alkynyl groups of this invention have 2, 3, 4, 5, or, 6 carbon atoms * and more preferably, from 2 , 3 , or 4 carbon atoms .
  • Cycloalkyl and cycloalkenyl groups have between 3 and 10 carbon atoms and are monocyclic or bicyclic, including linearly fused, bridged, or spirocyclic.
  • a cycloaliphatic group is, preferably, a cycloalkyl or a cylcoalkenyl . More preferred cycloaliphatic groups are 3-, 4-, 5-, 6-, or 7-membered rings that are, more preferably, cycloalkyl rings.
  • aromatic group refers to a 6-10-membered ring system that contains at least one aromatic ring.
  • aromatic rings include phenyl and naphthyl .
  • heteroaryl refers to ring system having 5-10 members and 1, 2, or 3 heteroatoms independently selected from N, N(R) , 0, S, SO, and S0 2 ., wherein at least one ring is heteroaromatic (e.g., pyridyl, thiophene, or thiazole) .
  • heteroaryl rings examples include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5- imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N- pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl) , 2-thiazolyl, 4- thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl) , triazolyl (e.g., 2-triazolyl and 5-triazolyl)
  • heterocycle refers to ring system having 3-10 members and 1, 2, or 3 heteroatoms independently selected from N, N(R) , 0, S, SO, and S0 2 , wherein no ring is aromatic (e.g., piperidine and morpholine) .
  • Preferred heterocyclyl groups are 5- or 6- membered rings having 1 or 2 heteroatoms .
  • heterocyclic rings examples include 3-1H- benzimidazol-2-one, 3- (1-alkyl) -benzimidazol-2-one, 2- tetrahydrofuranyl, 3-tetrahydrofuranyl, 2- tetrahydrothiophenyl , 3-tetrahydrothiophenyl, 2- morpholino, 3-morpholino, 4-morpholino, 2 ⁇ thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2- pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2- tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1- piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1- piperidinyl, 2-piperidinyl, 3-pipe
  • any of these cycloaliphatic, heterocyclyl, and heteroaryl groups are optionally fused with a 5- or 6- membered aryl or heteroaryl ring.
  • each of any aliphatic, aryl, cycloaliphatic, heteroaryl, and heterocyclyl may contain appropriate substituents (preferably up to 5, more preferable up to 3, and even more preferably, 0 or 1) independently selected from, for example, carbonyl and R. Preferred substituents
  • R and J 2 are halogen, -OR 7 , -N0 2 , -CF 3 , -OCF 3 , -R 7 , oxo, -OR 7 , -O-benzyl, -O-phenyl, 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R 7 ) 2 , -C(0)R 7 , -COOR 7 or -CON(R 7 ) 2 , wherein R 7 is defined herein (and is preferably H, (Cl- C6)-alkyl, or (C2-C6) -alkenyl and alkynyl), with (C1-C6)- alkyl being most preferred) .
  • R is a substituent on a nitrogen atom
  • preferred R groups are selected from the group consisting of -R 7 , -SOR 7 , -S0 2 R 7 , -S0 2 N(R 7 ) 2 , -S0 3 R 7 , -C(0)R 7 , -C(0)C(0)R 7 , -C (0) C (0) OR 7 , -C(0)C(0)N(R 7 ) 2 , -C(0)CH 2 C(0)R 7 , -C(S)R 7 , -C(S)OR 7 , -C(0)0R 7 , -C(0)N(R 7 ) 2 , -C(S)N(R 7 ) 2 , - (CH 2 ) 0 _ 2 NHC (0) R 7 , -N(R 7 )N(R 7 )COR 7 ,
  • the compounds of the present invention are broad caspase inhibitors and have an improved ability over reported compounds to inhibit apoptosis (see Examples 42 and 43) .
  • this invention provides a compound of formula la or lb
  • R 1 , R 2 , R 3 , and R 4 are as defined in any of the embodiments herein.
  • the compound of formula I of present invention provides a compound of formula II, selected from Table 1 below:
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising: 5 a) a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable carrier, adjuvant or vehicle.
  • the compounds of this invention may be prepared in general by methods known to those skilled in the art for analogous compounds and by the preparative examples that follow. For the purposes of illustration, the following Schemes I-III for the synthesis of the compounds of the present invention are provided. It should be understood that any protective group depicted in the schemes may be varied as appropriate in view of compatibility with other substituents .
  • Various protecting groups may be used in the methods of this invention (see, e.g., T.W. Greene & P.G.M Wutz, "Protective Groups in Organic Synthesis", 3 rd Edition, John Wiley & Sons, Inc. (1999) and the earlier editions of this book) .
  • Typical functional groups that must be protected are amines. Any amines and other functional groups may be protected according to methods known in the art. Compounds, including amines, may be used with or without isolation from the reaction mixtures .
  • EDC is 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide
  • HOBt is 1-hydroxybenzotriazole
  • THF is tetrahydrofuran
  • TFA is trifluoroacetic acid
  • DCM is dichloromethane
  • DMAP is 4-dimethylaminopyridine.
  • Acid 1 is coupled to amino alcohol 2.
  • the coupling is depicted using EDC/DMAP/HOBt/THF, however, other suitable conditions may also be used.
  • an amino ketone may be used, in place of the amino alcohol, thus avoiding the subsequent oxidation step.
  • fluoromethyl ketones where R 5 is
  • the amino alcohol 2 may be obtained according to the method of Revesz et al., Tetrahedron Lett . 1994, 35, 9693.
  • R 5 is -CH 2 0-2, 3, 5, 6-tetrafluorophenyl
  • amino alcohol 2 may be obtained by methods analogous to those of Semple et al . , Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1337 (Scheme II) .
  • R 4 in 3 is preferably an ester that is hydrolyzed in the final step of the scheme. If that ester is a t-butyl ester (i.e., if R 4 is C ⁇ 2tBu) , treatment -with trifluoroacetic acid will give the acid.
  • the ester is preferably a t-butyl ester when the other substituents in I are compatible with acidic conditions .
  • R 4 in product I is an ester
  • the desired ester may be prepared by esterifying the corresponding acid or by having the desired ester group already present in compound 2.
  • KF potassium fluoride
  • DMF N,N- dimethylformamide
  • ArOH 2, 3 , 5, 6-tetrafluorophenol
  • THF tetahydrofuran
  • MeOH methanol.
  • Lutidine/DCM (d) NaH/THF; (e) Rl-Cl/Et 3 N/DMAP/DCM; (f)
  • Another embodiment of this invention provides a process for preparing a compound of formula I:
  • R 1 , R 2 , R 3 , R 4 and R 5 are as defined in any of the embodiments herein, comprising:
  • R 9 is -N0 2 , -C(0)0R 10 , R 6 C(0)N(H)-, R 6 S0 2 N(H)-,
  • R 5 0C(0)N(H)-, (R 6 ) 2 NC(0)N(H)-, R 6 C (0) C (0) N (H) - , R 6 N(H)-, (R 6 ) 2 NC(0)C(0)N(H)-, or R 6 OC (0) C (O)N(H) - ;
  • R 10 is independently hydrogen, (C1-C12) -aliphatic- (C3- C10) -cycloaliphatic-, (C6-C10) -aryl-, (C3-C10)- heterocyclyl-, (C5-C10) -heteroaryl-, (C3-C10)- cycloaliphatic- (C1-C12) -aliphatic-, (C6-C10) -aryl- (Cl- C12) -aliphatic-, (C3-C10) -heterocyclyl- (C1-C12) - aliphatic-, (C5-C10) -heter
  • R 4 and R 5 are as defined in any of the embodiments of formula (I) herein; in the presence of peptide coupling conditions and a solvent; provided that if Y is an OH group, then the process further comprises (b) oxidizing the OH group to provide the compound of formula (I) ; and provided that if R 9 is -N0 2 , -C(0)0R 10 , or -CN, the process comprises the further step of converting the -N0 2 , -C(0)0R 10 , or -CN into R 6 C(0)N(H)-, R 6 S0 2 N(H)-, R 6 OC(0)N(H)-, (R 5 ) 2 NC(0)N(H)-, R 6 C (0) C (O)N(H) -, R 6 N(H)- (R 6 ) 2 NC(0)C(0)N(H)-, or R 6 OC (0) C (O)N(H) - .
  • the coupling conditions may be any known to skilled practitioners for forming peptidyl bonds. Preferred coupling conditions are EDC/DMAP/HOBt . A preferred solvent in the above embodiment is THF. [0057] In a preferred embodiment, the compound of formula (III) :
  • R 10 a protecting group
  • preferred deprotecting conditions include acid hydrolysis.
  • a preferred acid is TFA.
  • a ' preferred solvent is DCM. More preferably the solvent and the hydrolyzing conditions comprise TFA and DCM.
  • R 10 is methyl or ethyl, then preferred deprotecting conditions would be basic (e.g., aqueous NaOH). If R 10 is benzyl , then the benzyl group could be removed by hydrogenolysis .
  • X is a suitable leaving group; and R 3 and R 10 are as defined herein; in the presence of a solvent and a base.
  • X is -I, -Br, -Cl, -OH, an alkylsulfonate, or an aryl sulfonate.
  • an appropriate leaving group may be generated in situ (e.g., as in the Mitsunobu reaction) .
  • Preferred sulfonates include -O-trifluoromethanesulfonate, -0- methanesulfonate, -O-benzenesulfonate, -O-p- toluenesulfonate, -O-m-nitrobenzenesulfonate, and -0-p- nitrobenzenesulfonate.
  • Suitable leaving groups useful in the methods of this invention are well known in the art. See, e.g., "March's Advanced Organic Chemistry", 5 th Ed., Ed.: Smith, M.B. and March, J. , John Wiley & Sons, New York (2001) .
  • Suitable bases include any that may remove a proton from the hydroxy group in (V) .
  • bases include BuLi, LDA, LHMDS, and NaH.
  • the base is NaH.
  • Another embodiment of this invention provides a process for preparing a compound of formula (VIII) :
  • R 2 is -CF 3 , -CI, -OR 7 , -N0 2 , -OCF 3 , -CN, or R 8 ;
  • R 3 , R 8 , R 9 , and R 10 are as defined herein; comprising the step of (e) reacting a compound of formula (IX) :
  • X is a suitable leaving group; in the presence of a solvent and a base.
  • X is -I, -Br, -Cl, -OH, an alkylsulfonate, or an aryl sulfonate.
  • an appropriate leaving group may be generated in situ (e.g., as in the Mitsunobu reaction) .
  • Preferred sulfonates include -0-trifluoromethanesulfonate, -0- methanesulfonate, -O-benzenesulfonate, -O-p- toluenesulfonate, -O-m-nitrobenzenesulfonate, and -O-p- nitrobenzenesulfonate .
  • Any solvent is compatible with the generation of anions may be used.
  • Such solvents include DMF, toluene, and THF.
  • the solvent is THF.
  • Suitable bases include any that may remove a proton from the hydroxy group in (V) .
  • Such bases include BuLi, LDA, LHMDS, and NaH.
  • the base is NaH.
  • Another embodiment of this invention provides a process for preparing a compound of formula (I) :
  • R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in any of the embodiments herein, comprising: (a) reacting a compound of formula (VI or IX) :
  • R 9 is -N0 2 , -C(0)0R 10 -CN, R 6 C(0)N(H)-, R 6 S0 2 N(H)
  • R 2 , R 3 and R 6 are as defined herein; with a compound of formula (X) :
  • the compounds of this invention can be assayed for their, ability to inhibit the release of IL-l ⁇ , caspase activity, or apoptosis directly. Assays for each of the activities are known in the art. Selected assays are described below. [0069] If pharmaceutically acceptable salts of the compounds of this invention are utilized in these compositions, those salts are preferably derived from inorganic or organic acids and bases.
  • acid salts include the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl- propionate, picrate, pivalate, propionate, succinate, tartrate, thi
  • N-methyl-D-glucamine and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others . Water or oil-soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides
  • dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides
  • compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties.
  • modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • compositions include, but are not limited to, ion exchangers, ' alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers , polyethylene glycol and wool fat.
  • ion exchangers such as human serum albumin
  • buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salt
  • compositions of this invention are formulated for pharmaceutical administration to a mammal, preferably a human being .
  • Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents .
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol .
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • a long-chain alcohol diluent or dispersant such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents, such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs .
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers .
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • the pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation.
  • compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons , and/or other conventional solubilizing or dispersing agents .
  • compositions are particularly useful in therapeutic applications relating to an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, or various forms of liver disease.
  • Such diseases include those related to rheumatology and autoimmunity, such as rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, myasthenia gravis, autoimmune neutropenia, autoimmune hemolytic anemia, thrombocytopenia, juvenile rheumatoid arthritis, gout, Behcet's syndrome, Still's syndrome, macrophage activation syndrome, and sarcoidosis; auto-inflammatory syndromes, such as cryopyrin-associated Periodic Syndromes, (including Muckle-Wells syndrome, familial cold urticaria, chronic infantile neurological cutaneous and articular syndrome (a.k.a.
  • pulmonary fibrosis atopic dermatitis, scarring, alopecia, acne vulgaris, and pemphigus
  • dermatology such as psoriasis, atopic dermatitis, scarring, alopecia, acne vulgaris, and pemphigus
  • respiratory such as asthma, adult respiratory distress syndrome, cystic fibrosis, emphysema, chronic bronchitis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis
  • internal medicine such as inflammatory peritonitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, autoimmune gastritis, H.pylori-associated gastric and duodenal ulcer disease, diabetes, pancreatitis, glomerulonephritis, chronic active hepatitis, excess dietary alcohol intake disease, renal disease, polycystic kidney disease, burn
  • GVHD host disease
  • organ transplant rejection organ transplant rejection
  • oncology such as leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, and multiple myeloma
  • cardiovascular such as chronic heart disease, acute heart disease, myocardial infarction, myocardial ischemia, congestive heart failure, atherosclerosis, coronary artery bypass graft (CABG) , and acute coronary syndrome
  • CABG coronary artery bypass graft
  • the central and peripheral nervous systems such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV- related encephalitis, traumatic brain injury, spinal cord injury, neurological damage due to stroke,
  • the compounds and compositions are also useful in treating complications associated with coronary artery bypass grafts .
  • the amount of compound present in the above-described compositions should be sufficient to cause a detectable decrease in the severity of the disease or in caspase activity and/or cell apoptosis, as measured by any of the assays known in the art.
  • compositions of this invention may further comprise another therapeutic agent.
  • agents include, but are not limited to, thrombolytic agents such as tissue plasminogen activator and streptokinase.
  • the second agent may be administered either as a separate dosage form or as part of a single dosage form with the compounds or compositions of this invention. Accordingly, a combined preparation for simultaneous, separate, or sequential use is provided by this invention.
  • Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of a disease involving caspase activity and/or apoptosis.
  • the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w) .
  • compositions of this invention comprise a combination of a compound of formula I and one or more additional therapeutic or prophylactic agents
  • both the compound and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the invention provides a method of treating a mammal, having one of the aforementioned diseases, comprising the step of administering to said mammal a pharmaceutically acceptable composition described above.
  • the patient is also administered another therapeutic agent or caspase inhibitor, it may be delivered together with the compound of this invention in a single dosage form, or, as a separate dosage form.
  • the other caspase inhibitor or agent may be administered prior to, at the same time as, or following administration of a pharmaceutically acceptable composition comprising a compound of this invention.
  • reaction mixture was stirred at room temperature for 90 minutes and quenched with aqueous ammonium chloride (10 mL) . Most of the solvent was evaporated and the residue was partitioned between EtOAc and saturated aqueous NHC1. The organic layer was washed with brine (30 mL) , dried (MgS0) , filtered and evaporated.
  • the resulting mixture was kept at 0°C for 2hr, diluted with ethyl acetate, then poured into a 1:1 mixture of saturated aqueous sodium hydrogen carbonate and saturated aqueous sodium thiosulfate. The organic layer was removed and the aqueous layer re-extracted with ethyl acetate. The combined organic extracts were dried (Magnesium sulfate) and concentrated.
  • the assays for caspase inhibition are based on the cleavage of a fluorogenic substrate by recombinant, purified human Caspases -1, -3, or -8.
  • the assays are run in essentially the same way as those reported by Garcia-Calvo et al. (J " . Biol . Chem. 273 (1998), 32608- 32613), using a substrate specific for each enzyme.
  • the substrate for Caspase-1 is Acetyl-Tyr-Val-Ala-Asp-amino- 4-methylcoumarin.
  • the substrate for Caspases -3 and -8 is Acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin.
  • Human blood is freshly drawn from healthy donors and diluted 1:2 in PBS.
  • 50ml of prediluted test compound in RPMI medium and 10 ml LPS (5ng/ml final concentration on the plate) are added (LPS, Serotype 0111:B4, Sigma L3012). After stimulation for 18 hours supernatants are collected and assayed for IL-l ⁇ levels using the appropriate ELISA kit
  • Table 2 shows inhibition of IL-l ⁇ secretion from human whole blood for selected compounds of this invention as determined individually by the above methods .
  • Table 2 Inhibition of IL-l ⁇ secretion
  • Cortical neurons are dissociated from Wistar rat embryos (E17) by a modification of the procedure of Rogers et al. 1997, Brain Res . Bulletin, 44:131. Briefly, cerebral cortices are isolated aseptically from 15-20 Wistar rat embryos. A cell suspension is prepared by mincing the cerebral cortices and digesting them with papain. Cells are washed with ovomucoid enzyme inhibitor and DNasel and plated onto Poly-D lysine coated plates in high glucose DMEM containing 10% heat-inactivated fetal calf serum, L-glutamine, penicillin and streptomycin.
  • the yield of neurons is 10x7 per embryo and they are 80-
  • the neurons are cultured in complete medium at
  • Cellular apoptosis may be induced by the binding of Fas ligand (FasL) to its receptor, CD95 (Fas) .
  • CD95 is one of a family of related receptors, known as death receptors, which can trigger apoptosis in cells via activation of the caspase enzyme cascade. The process is initiated by the binding of the adapter molecule FADD/MORT-1 to the cytoplasmic domain of the CD-95 receptor-ligand complex. Caspase-8 then binds FADD and becomes activated, initiating a cascade of events that involve the activation of downstream caspases and subsequent cellular apoptosis.
  • Apoptosis can also be induced in cells expressing CD95 e.g., the Jurkat E6.1 T cell lymphoma cell line, using an antibody, rather than FasL, to crosslink the cell surface CD95.
  • Anti-Fas- induced apoptosis is also triggered via the activation of caspase-8. This provides the basis of a cell based assay to screen compounds for inhibition of the caspase-8- mediated apoptotic pathway.
  • Jurkat E6.1 cells are cultured in complete medium consisting of RPMI-1640 (Sigma No) + 10% foetal calf serum (Gibco BRL No.10099-141) + 2mM L-glutamine (Sigma No. G-7513). The cells are harvested in log phase of growth. 100 ml of cells at 5-8x105 cells/ml are transferred to sterile 50ml Falcon centrifuge tubes and centrifuged for 5 minutes at lOOxg at room temperature. The supernatant is removed and the combined cell pellets resuspended in 25ml of complete medium. The cells are counted and the density adjusted to 2xl06cells/ml with complete medium.
  • test compound is dissolved in dimethyl sulfoxide (DMSO) (Sigma No. D-2650) to give a lOOmM stock solution. This is diluted to 400 ⁇ M in complete medium, then serially diluted in a 96-well plate prior to addition to the cell assay plate.
  • DMSO dimethyl sulfoxide
  • lOO ⁇ l of the cell suspension (2x106 cells) is added to each well of a sterile 96-well round-bottomed cluster plate (Costar No. 3790) .
  • 50 ⁇ l of compound solution at the appropriate dilution and 50 ⁇ l of anti-Fas antibody, clone CH-11 (Upstate, Cat No.l 544 675) at a final concentration of lOng/ml, are added to the wells.
  • Control wells are set up minus antibody and minus compound but with a serial dilution of DMSO as vehicle control.
  • the plates are incubated for 16-18hrs at 37°C in 5% C02 and 95% humidity.
  • Apoptosis of the cells is measured by the quantitation of DNA fragmentation using a 'Cell Death Detection Assay' from Roche diagnostics, No. 1544 675. After incubation for 16-18hrs the assay plates are centrifuged at lOOxg at room temperature for 5 minutes. 150 ⁇ l of the supernatant are removed and replaced by 150 ⁇ l of fresh complete medium. The cells are then harvested and 200 ⁇ l of the lysis buffer supplied in the assay kit are added to each well. The cells are triturated to ensure complete lysis and incubated for 30 minutes at 4°C. The plates are then centrifuged at 1900xg for 10 minutes and the supernatants diluted 1:20 in the incubation buffer provided.
  • OD405nm is measured 20 minutes after addition of the final substrate in a SPECTRAmax Plus plate reader (Molecular Devices) .
  • OD405nm is plotted versus compound concentration and the IC50 values for the compounds are calculated using the curve-fitting program SOFTmax Pro (Molecular Devices) using the four parameter fit option.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Addiction (AREA)

Abstract

The present invention provides a compound of formula (I), wherein R1, R6C(O)-, HC(O)-, R6SO2-, R6OC(O)-, (R6)2NC(O)-, (R6) (H) NC (O)-, R6C (O) C (O) -, R6-, (R6) 2NC (O) C (O)-, R6 (H) NC (O) C (O)-, or R6OC (O) C (O)-; R2 is hydrogen, CF3, -halo, -OR7, -NO2, -OCF3, -CN, or R8; R3 is hydrogen or (C1-C4) -aliphatic-; R4 is -COOH or -COOR8; R5 is -CH2F or -CH2O-2, 3, 5, 6-tetrafluorophenyl. The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated diseases and processes for preparing the compounds of the invention.

Description

CASPASE INHIBITORS AND USES THEREOF
Field of the Invention
[0001] This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit caspases that mediate cell apoptosis and inflammation. The invention also 'relates to processes for preparing these compounds. The invention further relates .to methods of using the compounds and pharmaceutical compositions of this invention to treat diseases where caspase activity is implicated. Background of the Invention
0002] Apoptosis, or programmed cell death, is a principal mechanism by which organisms eliminate unwanted cells. The deregulation of apoptosis, either excessive apoptosis or the failure to undergo it, has been implicated in a number of diseases such as cancer, acute inflammatory and autoimmune disorders, ischemic diseases and certain neurodegenerative disorders (see generally Science, 1998, 281, 1283-1312; Ellis et al . , Ann. J?e . Cell . Biol . , 1991, 7, 663). [0003] Caspases are a family of cysteine protease enzymes that are key mediators in the signaling pathways for apoptosis and cell disassembly (Thornberry, Chem. Biol . , 1998, 5, R97-R103). These signaling pathways vary depending on cell type and stimulus, but all apoptosis pathways appear to converge at a common effector pathway leading to proteolysis of key proteins. Caspases are involved in both the effector phase of the signaling pathway and further upstream at its initiation. The upstream caspases involved in initiation events become activated and in turn activate other caspases that are involved in the later phases of apoptosis. [0004] Caspase-1, the first identified caspase, is also known as interleukin converting enzyme or "ICE."
Caspase-1 converts precursor interleukin-lβ ("pIL-lβ") to the pro-inflammatory active form by specific cleavage of pIL-lβ between Asp-116 and Ala-117. Besides caspase-1 there are also eleven other known human caspases, all of which cleave specifically at aspartyl residues. They are also observed to have stringent requirements for at least four amino acid residues on the N-terminal side of the cleavage site. [0005] The caspases have been classified into three groups depending on the amino acid sequence that is preferred or primarily recognized. The group of caspases, which includes caspases 1, 4, 5 and 13, have been shown to prefer hydrophobic aromatic amino acids at position 4 on the N-terminal side of the cleavage site. Another group which includes caspases 2, 3 and 7, recognize aspartyl residues at both positions 1 and 4 on the N-terminal side of the cleavage site, and preferably a sequence of Asp-Glu-X-Asp. A third group, which includes caspases 6, 8, 9 and 10, tolerate many amino acids in the primary recognition sequence, but seem to prefer residues with branched, aliphatic side chains such as valine and leucine at position 4. [0006] The caspases have also been grouped according to their perceived function. The first subfamily consists of caspases-1 (ICE), 4, 5 and 13. These caspases have been shown to be involved in pro- inflammatory cytokine processing and therefore play an important role in inflammation. Caspase-1, the most studied enzyme of this class, activates the IL-lβ precursor by proteolytic cleavage. This enzyme therefore plays a key role in the inflammatory response. Caspase-1 is also involved in the processing of interferon-γ inducing factor (IGIF, also known as IL-18) which stimulates the production of interferon gamma, a key immunoregulator that modulates antigen presentation, T- cell activation and cell adhesion. [0007] The remaining caspases make up the second and third subfamilies. These enzymes are of central importance in the intracellular signaling pathways leading to apoptosis. One subfamily consists of the enzymes involved in initiating events in the apo otic pathway, including transduction of signals from the plasma membrane. Members of this subfamily include caspases-2, 8, 9 and 10. The other subfamily, consisting of the effector capsases 3, 6 and 7, are involved in the final downstream cleavage events that result in the systematic breakdown and death of the cell by apoptosis. Caspases involved in the upstream signal transduction activate the downstream caspases, which then disable DNA repair mechanisms, fragment DNA, dismantle the cell cytoskeleton and finally fragment the cell . [0008] Knowledge of the four amino acid sequence primarily recognized by the caspases has been used to design caspase inhibitors. Reversible tetrapeptide inhibitors have been prepared having the structure CH3CO-[P4]-[P3]-[P2]-CH(R)CH2C02H where P2 to P4 represent- an optimal amino acid recognition sequence and R is an aldehyde, nitrile or ketone capable of binding to the caspase cysteine sulfhydryl. Rano and Thornberry, Chem. Biol . 4, 149-155 (1997); Mjalli, et al., Bioorg. Med. Chem. Lett . 3, 2689-2692 (1993); Nicholson et al., Nature 376, 37-43 (1995) . Irreversible inhibitors based on the analogous tetrapeptide recognition sequence have been prepared where R is an acyloxymethylketone -COCH2OCOR' . R' is exemplified by an optionally substituted phenyl such as 2, 6-dichlorobenzoyloxy and where R is C0CH2X where X is a leaving group such as F or Cl . Thornberry et al . , Biochemistry 33, 3934 (1994); Dolle et al . , J Med. Chem. 37, 563-564 (1994).
[0009] The utility of caspase inhibitors to treat a variety of mammalian disease states associated with an increase in cellular apoptosis has been demonstrated using peptidic caspase inhibitors. For example, in rodent models caspase inhibitors have been shown to reduce infarct size and inhibit cardiomyocyte apoptosis after myocardial infarction, to reduce lesion volume and neurological deficit resulting from stroke, to reduce post-traumatic apoptosis and neurological deficit in traumatic brain injury, to be effective in treating fulminant liver destruction, and to improved survival after endotoxic shock. Yaoita et al., Circulation, 97, 276 (1998); Endres et al . , J" CereJbral Blood Flow and Metabolism, 18, 238, (1998); Cheng et al., J. Clin. Invest., 101, 1992 (1998); Yakovlev et al . , J"
Neuroscience, 17, 7415 (1997); Rodriquez et al . , J. Exp. Med. , 184, 2067 (1996); Grobmyer et al., Mol . Med. , 5, 585 (1999). [0010] In general, the peptidic inhibitors described above are very potent against some of the caspase enzymes. However, this potency has not always been reflected in cellular models of apoptosis . In addition peptide inhibitors are typically characterized by undesirable pharmacological properties such as poor oral absorption, poor stability and rapid metabolism. Plattner and Norbeck, in Drug Discovery Technologies, Clark and Moos, Eds. (Ellis Horwood, Chichester, England, 1990) .
[0011] Recognizing the need to improve the pharmacological properties of. the peptidic caspase inhibitors, peptidomimetic inhibitors have been reported. Amongst these, inhibitors where the P3 amino acid has been replaced by derivatives of 3-aminopyridin-2-ones and 5-aminopyrimidin-4-ones have been reported (U.S. Patent 5,756,466 (Bemis et al.); PCT Publication No. WO 95/35308 (Be is et al . ) ; Dolle et al . J. Med. Chem. 39, 2438, (1996); Golec et al . Bioorg. Med. Chem. Lett . 7, 2181, (1997); Se ple et al, Biorg. Med. Chem. Lett . 7, 1337, (1997) ) .
[0012] Due to the inherent problems of the peptidic inhibitors, there continues to be a need for small molecule, nonpeptide caspase inhibitors that are potent, stable, and penetrate membranes to provide effective inhibition of apoptosis in vivo. Such compounds would be extremely useful in treating the aforementioned diseases where caspase enzymes play a role. Summary of the Invention [0013] The present invention provides a compound of formula I :
Figure imgf000007_0001
wherein: R1, R2, R3, R4, and R5 are as defined herein. [0014] The present invention also provides pharmaceutical compositions comprising a compound of formula I and methods using such compounds and compositions for treating caspase-mediated diseases. The present invention also provides processes for preparing the compounds of formula I .
Detailed Description of the Invention [0015] The present invention provides a compound of formula I :
Figure imgf000007_0002
wherein:
R1 is R5C(0)-, HC(O)-, R6S02-, R6OC(0)-, (R6)2NC(0)-,
(R6) (H)NC(O)-, R6C(0)C(0)-, R6-, (R6) 2NC (0) C (0) - ,
(R6) (H)NC(0)C(0)-, or R60C (0) C (O) -;
R2 is hydrogen, -CF3, halo, -OR7, -N02, -OCF3, -CN, or R8;
R3 is hydrogen or (C1-C4) -aliphatic-;
R4 is -COOH or -C00R8;
R5 is -CH2F or -CH20-2 , 3 , 5 , 6-tetraf luorophenyl ; R5 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- CIO) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10)- heteroaryl (C1-C12) -aliphatic-, or two R6 groups bound to the same atom form together with that atom a 3- to lO-membered aromatic or nonaromatic ring; wherein the ring is optionally fused to a (C6-C10)aryl, (C5- CIO) heteroaryl, (C3-CIO) cycloalkyl, or a (C3-
C10) heterocyclyl; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R) , S, SO, and S02; and wherein R5 is substituted with up to 6 substituents independently selected from R;
R is halogen, -OR7, -OC (0)N(R7)2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, =NR7, =N(0R7) , 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, ~S02N(R7)2, -SO3R7, -C(0)R7, -C(0)C(0)R7, -C(0)C(0)0R7, -C (0) C (O)N(R7) 2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)OR7, -C(0)OR7, -OC(0)R7,
-C(0)N(R7)2, -0C(0)N(R7)2, -C(S)N(R7)2, - (CH2) 0-2NHC (0) R7, -N(R7)N(R)COR7, ~N(R7)N(R7)C(0)OR7, -N(R7)N(R7) C0N(R7) 2 , -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7) C (0) OR7, -N(R7) C (O)R7, -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S)N(R7) 2, -N(COR7)COR7, -N(0R7)R7, -C (=NH)N(R7) 2, -C (0)N(0R7) R7, -C(=N0R7)R7, -OP(0) (OR7)2, -P(0)(R7)2, -P(0)(OR7)2, or -P(0) (H) (OR7); two R7 groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or non- aromatic ring having up to 3 heteroatoms independently selected from N, N(R) , 0, S, SO, or S02, wherein the ring is optionally fused to a (C6-C10) aryl, (C5- C10) heteroaryl, (C3-C10) cycloalkyl, or a (C3- C10) heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J2; or each R7 is independently selected from: hydrogen- , (C1-C12) -aliphatic-,
(C3-C10) -cycloaliphatic-,
(C3-C10) -cycloaliphatic- (C1-C12) -aliphatic-, (Cδ-ClO)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-CIO) -heterocyclyl-,
(C6-C10) -heterocyclyl- (C1-C12) aliphatic-, (C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12 ) -aliphatic-; wherein R7 has up to 3 substituents selected independently from J2; and
J2 is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, =NR7, =NOR7, 1, 2-methylenedioxy, 1,2- ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C(0)C(0)OR7, -C(0)C(0)N(R7)2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)OR7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, -C(S)N(R7)2, -(CH2)0-2NHC(O)R7, -N(R7)N(R7) COR7, -N(R7)N(R7)C(0)OR7, -N(R7)N(R7)CON(R7)2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7)C(0)OR7, -N(R7) C (O) R7, -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S)N(R7) 2, -N(COR7) COR7, -N(0R7)R7, -CN, -C (=NH)N(R7) 2, -C(0)N(OR7)R7, -C(=NOR7)R7, -OP (O) (OR7) 2, -P(0)(R7)2, -P(O) (OR7) 2, or -P(O) (H) (OR7) ; and R8 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- CIO) -aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, or (C5-C10)- heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N, N(R) , S, SO, and S02; and wherein R8 is optionally substituted with up to 6 substituents independently selected from R.
[0016] The present invention also provides a compound of formula I:
Figure imgf000010_0001
wherein:
R1 is R6C(0) R6S02-, R60C(0) (R6)2NC(0)-, R6C(0)C(0)-,
R° (R6)2NC(0)C(0)-, or R60C(0)C(0)
R is hydrogen, -CF3, halo, -OR , -N02, -OCF3, -CN, or R8;
R3 is hydrogen or (C1-C4) -aliphatic-; R4 is -COOH or -COOR8;
R5 is -CH2F or -CH20-2 , 3 , 5 , 6-tetrafluorophenyl;
R6 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- Cl0)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10) - heteroaryl (C1-C12) -aliphatic-, or two R6 groups bound to the same atom form together with that atom a 3- to 10-membered aromatic or nonaromatic ring; wherein the ring is optionally fused to a (C6-C10) aryl, (C5- C10) heteroaryl, (C3-C10) cycloalkyl, or a (C3- C10) heterocyclyl; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N(H) , N(R) , S, SO, and S02; and wherein R6 is substituted with up to 6 substituents independently selected from R;
R is halogen, -OR7, -OC (0)N(R7)2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, 1, 2-methylenedioxy, 1,2- ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -SO3R7, -C(0)R7, -C(0)C(0)R7, -C(0)CH2C(0)R7, -C(S)R7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, -C(S)N(R7)2, -(CH2)0-2NHC(O)R7, -N(R7)N(R7)COR7, -N(R7)N(R7) C (O) OR7 , -N(R7)N(R7)CON(R7)2/ -N(R7)S02R7, -N(R7) S02N(R7) 2, -N(R7)C(0)OR7, -N(R7)C(0)R7, -N(R7) C (S)R7, -N (R7) C (O)N(R7) 2, -N(R7)C(S)N(R7)2, -N(COR7)COR7, -N(OR)R7, -C (=NH)N (R7) 2 , -C(0)N(OR7)R7, -C(=NOR7)R7, -OP (0) (OR7) 2, -P(0)(R7)2, -P(O) (0R7)2/ or -P(O) (H) (OR7) ; two R7 groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or nonaromatic ring having up to 3 heteroatoms independently selected from N(H) , N(R) , 0, S, SO, or S02, wherein the ring is optionally fused to a (C6-C10) aryl, (C5- C10)heteroaryl, (C3-C10) cycloalkyl, or a (C3- CIO) heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J ; or each R7 is independently selected from: hydrogen- ,
(C1-C12) -aliphatic-, (C3-CIO) -cycloaliphatic-,
(C3-C10) -cycloaliphatic- (C1-C12) -aliphatic-, (C6-C10)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-CIO) -heterocyclyl-, (C6-C10) -heterocyclyl- (C1-C12) aliphatic-,
(C5-C10) -heteroaryl-, or (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein R7 has up to 3 substituents selected independently from J2; and
J2 is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, 1, 2-methylenedioxy, 1,2- ethy1enedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C(0)CH2C(0)R7, -C(S)R7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, -C(S)N(R7)2, -(CH2)0-2NHC(O)R7, -N(R7)N(R7) COR7, -N(R7)N(R7)C(0)OR7, -N(R7) N(R7) CON(R7) 2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7)C(0)OR7, -N(R7) C (0) R7, -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S)N(R7) 2, -N(C0R7)C0R7, -N(0R7)R7, -CN, -C (=NH)N(R7) 2, -C(0)N(OR7)R7, -C(=NOR7)R7, -OP (O) (OR7) 2, -P(0)(R7)2, -P(O) (OR7)2, or -P(O) (H) (OR7) ; and
R8 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- CIO) -heterocyclyl- (C1-C12) -aliphatic-, or (C5-C10)- heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N(H) , N(R) , S, SO, and S02. [0017] Another embodiment of this invention provides a compound wherein, R1 is R6C(0)-, R6S02-, or R6-. In a preferred embodiment, Rα is R6C(0)-. In another preferred embodiment, R1 is R6S02-. In yet another preferred embodiment, R1 is R6-.
[0018] Another embodiment of this invention provides a compound wherein R1 is (R6)2NC(0)- or (R6)0C(0)-. In a preferred embodiment, R1 is (R6)2NC(0)-. In another preferred embodiment, R1 is (R6) (H)NC (0) - . In yet another preferred embodiment, R1 is (R5)0C(0)-. [0019] In one embodiment of this invention, each R6 is independently (C1-C4) -aliphatic-, (C3-C10)- cycloaliphatic, (C3-CIO) -heterocyclyl, (C5-C10)- heteroaryl, (C6-C10) -aryl-, or (C6-C10) -aryl- (C1-C12) - (it being understood that optionally up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R) , S, SO, and S02; and wherein R6 is optionally substituted with up to 6 substituents independently selected from R or R6 is substituted as disclosed in any of the embodiments herein) .
[0020] In another embodiment, each R6 is independently H, (C1-C4) -aliphatic- or (C6-C10) -aryl- or each R6 together with the N-atom is a (C3-C7) -cycloaliphatic. [0021] In another embodiment, each R6 is independently (C1-C4) -aliphatic-, (C5-C10) -heteroaryl-, or (C6-C10)- aryl-, wherein the heteroaryl or aryl is optionally substituted or wherein each R6 together with the N-atom is a (C3-C7) -cycloaliphatic group. [0022] In another embodiment, each R6 is independently (C1-C4) -aliphatic- or (C6-C10) -aryl-, wherein the aryl is optionally substituted or wherein each Rs together with the N-atom is a (C3-C7) -cycloaliphatic. [0023] In yet another embodiment, each R6 is independently (C1-C4) -aliphatic-, (C3-C7) -cycloaliphatic, (C6-C10) -aryl-, (C5-C10) -heteroaryl, wherein the heteroaryl and aryl are independently and optionally substituted, or each R6 together with the N-atom is a (C3-C7) -cycloaliphatic. [0024] According to a preferred embodiment of this invention, R2 is hydrogen, C1-, C2-, C3-, or C4-alkyl-,
-CF3, -CI, -OR7, -N02, -0CF3, or -CN. More preferably, R2 is hydrogen, Cl-alkyl-, C2-alkyl-, or CF3. More preferably, R2 is hydrogen or CF3. [0025] According to another preferred embodiment, R3 is •ethyl .
[0026] According to another preferred embodiment, R5 is -CH20-2 ,3,5, 6-tetrafluorophenyl . [0027] According to another preferred embodiment, R5 is -CH2F.
[0028] According to another preferred embodiment, R8 is (C1-C12) -alkyl. More preferably, R8 is (C1-C4) -alkyl . [0029] According to a preferred embodiment, each R and J2 are independently halogen, -OR7, -OC (O) (R7) 2, -N02, -CN, -CF3, -OCF3, -R7, oxό, 1,2-methylenedioxy, 1,2- ethylenedioxy, -N(R7)2, -C(0)R7, -C(0)C(0)R7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, or -OC (O)N(R7) 2. [0030] As used herein, the carbon atom designations may have the indicated integer and any intervening integer. For example, the number of carbon atoms in a (C1-C4) -alkyl group is 1, 2, 3, or 4. It should be understood that these designation refer to the total number of atoms in the appropriate group. For example, in a (C3-C10) -heterocyclyl the total number of carbon atoms and heteroatoms is 3 (as in aziridine) , 4, 5, 6 (as in morpholine) , 7, 8, 9, or 10.
[0031] As used herein, an aliphatic group includes straight-chained and branched groups having the specified number of atoms. If the number of atoms is unspecified, the aliphatic group has from 1 to 12 carbon atoms . As would be understood, alkenyl and/or alkynyl aliphatic groups have a minimum of 2 carbon atoms . Preferred aliphatic groups are alkyl groups (preferably having from 1 to 6 atoms) .
[0032] Accordingly, unless otherwise specified, preferred aliphatic groups of this invention are alkyl groups and have 1, 2, 3, 4, 5, or 6 carbon atoms . More preferred alkyl groups have 1, 2, 3, or 4 carbon atoms. Preferred alkenyl and alkynyl groups of this invention have 2, 3, 4, 5, or, 6 carbon atoms* and more preferably, from 2 , 3 , or 4 carbon atoms . [0033] Cycloalkyl and cycloalkenyl groups have between 3 and 10 carbon atoms and are monocyclic or bicyclic, including linearly fused, bridged, or spirocyclic. A cycloaliphatic group is, preferably, a cycloalkyl or a cylcoalkenyl . More preferred cycloaliphatic groups are 3-, 4-, 5-, 6-, or 7-membered rings that are, more preferably, cycloalkyl rings.
[0034] As used herein, "aromatic group" or "aryl" refers to a 6-10-membered ring system that contains at least one aromatic ring. Example of aromatic rings include phenyl and naphthyl .
[0035] As used herein a "heteroaryl" refers to ring system having 5-10 members and 1, 2, or 3 heteroatoms independently selected from N, N(R) , 0, S, SO, and S02., wherein at least one ring is heteroaromatic (e.g., pyridyl, thiophene, or thiazole) . Preferred heteroaryl groups are 5- or 6-membered rings having 1 or 2 heteroatoms. In certain embodiments of this invention, more preferred heteroaryl groups are those that have contain a "=N" group. [0036] Examples of heteroaryl rings include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5- imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N- pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl) , 2-thiazolyl, 4- thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl) , triazolyl (e.g., 2-triazolyl and 5-triazolyl) , 2-thienyl, 3-thienyl, benzofuryl, benzothiophenyl, indolyl (e.g., 2- indolyl) , pyrazolyl (e.g., 2-pyrazolyl) , isothiazolyl, 1, 2, 3-oxadiazolyl, 1, 2, 5-oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 2, 3-triazolyl, 1, 2, 3-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 5-thiadiazolyl, purinyl, pyrazinyl, 1, 3 , 5-triazinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4- quinolinyl) , and isoquinolinyl (e.g., 1-isoquinolinyl, 3- isoquinolinyl, or 4-isoquinolinyl) . [0037] As used herein a "heterocycle" refers to ring system having 3-10 members and 1, 2, or 3 heteroatoms independently selected from N, N(R) , 0, S, SO, and S02, wherein no ring is aromatic (e.g., piperidine and morpholine) . Preferred heterocyclyl groups are 5- or 6- membered rings having 1 or 2 heteroatoms . [0038] Examples of heterocyclic rings include 3-1H- benzimidazol-2-one, 3- (1-alkyl) -benzimidazol-2-one, 2- tetrahydrofuranyl, 3-tetrahydrofuranyl, 2- tetrahydrothiophenyl , 3-tetrahydrothiophenyl, 2- morpholino, 3-morpholino, 4-morpholino, 2~thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2- pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2- tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1- piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1- piperidinyl, 2-piperidinyl, 3-piperi'dinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl, 1- imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5- imidazolidinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothiolane, benzodithiane, and 1, 3-dihydro-imidazol-2-one.
[0039] Any of these cycloaliphatic, heterocyclyl, and heteroaryl groups are optionally fused with a 5- or 6- membered aryl or heteroaryl ring. Furthermore, each of any aliphatic, aryl, cycloaliphatic, heteroaryl, and heterocyclyl may contain appropriate substituents (preferably up to 5, more preferable up to 3, and even more preferably, 0 or 1) independently selected from, for example, carbonyl and R. Preferred substituents
(including R and J2) are halogen, -OR7, -N02, -CF3, -OCF3, -R7, oxo, -OR7, -O-benzyl, -O-phenyl, 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -C(0)R7, -COOR7 or -CON(R7)2, wherein R7 is defined herein (and is preferably H, (Cl- C6)-alkyl, or (C2-C6) -alkenyl and alkynyl), with (C1-C6)- alkyl being most preferred) . It should be understood that this definition would include a perfluorinated alkyl group . [0040] In embodiments of this invention where R is a substituent on a nitrogen atom, preferred R groups are selected from the group consisting of -R7, -SOR7, -S02R7, -S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C (0) C (0) OR7, -C(0)C(0)N(R7)2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)OR7, -C(0)0R7, -C(0)N(R7)2, -C(S)N(R7)2, - (CH2) 0_2NHC (0) R7, -N(R7)N(R7)COR7, -N(R7) N(R7) C (0) OR7, -N(R7)N(R7) CON(R7) 2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7) C (0) OR7, -N(R7) C (O) R7, -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N (R7) C (S)N(R7) 2, -N(COR7)COR7, -N(OR7)R7, -C (=NH) N(R7) 2 , -C (0) N (OR7) R7, -C(=NOR7)R7, -0P(0) (OR7)2, -P(0)(R7)2, -P(0)(OR7)2, and -P(0) (H) (OR7), wherein R7 is defined herein (and is preferably H, (C1-C6) -alkyl, or (C2-C6) -alkenyl and alkynyl), with (C1-C6) -alkyl being most preferred). More preferably, such R groups are selected from the group consisting of -R7 and -C(0)R7. [0041] In preferred compounds of this invention, the stereochemistry is as depicted below:
Figure imgf000018_0001
[0042] Any of the embodiments disclosed herein may be combined to provide alternative embodiments of this invention. Specific embodiments of this invention may be selected from the substituents depicted in the compounds of Table 1
[0043] The compounds of the present invention are broad caspase inhibitors and have an improved ability over reported compounds to inhibit apoptosis (see Examples 42 and 43) .
[0044] According to a preferred embodiment, this invention provides a compound of formula la or lb
Figure imgf000018_0002
la lb; wherein R1, R2, R3, and R4 are as defined in any of the embodiments herein.
[0045] According to a more preferred embodiment, the compound of formula I of present invention provides a compound of formula II, selected from Table 1 below:
Figure imgf000018_0003
II -li
Figure imgf000019_0001
Figure imgf000020_0001
[0046] According to another embodiment, the present invention provides a pharmaceutical composition comprising: 5 a) a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable carrier, adjuvant or vehicle. [0047] It will be apparent to one skilled in the art
10 that certain compounds of this invention may exist in tautomeric forms or hydrated forms, all such forms of the compounds being within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the
15 structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, structures
20 depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention.
[0048] The compounds of this invention may be prepared in general by methods known to those skilled in the art for analogous compounds and by the preparative examples that follow. For the purposes of illustration, the following Schemes I-III for the synthesis of the compounds of the present invention are provided. It should be understood that any protective group depicted in the schemes may be varied as appropriate in view of compatibility with other substituents . [0049] Various protecting groups may be used in the methods of this invention (see, e.g., T.W. Greene & P.G.M Wutz, "Protective Groups in Organic Synthesis", 3rd Edition, John Wiley & Sons, Inc. (1999) and the earlier editions of this book) . Typical functional groups that must be protected are amines. Any amines and other functional groups may be protected according to methods known in the art. Compounds, including amines, may be used with or without isolation from the reaction mixtures .
Scheme I
Figure imgf000022_0001
I
Scheme I (a) EDC/DMAP/HOBt/ HF; (b) Dess-Martin periodinane; (c) TFA/DCM
[0050] In Scheme I above, the following abbreviations are used: EDC is 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide; HOBt is 1-hydroxybenzotriazole; THF is tetrahydrofuran; TFA is trifluoroacetic acid; DCM is dichloromethane; DMAP is 4-dimethylaminopyridine. Acid 1 is coupled to amino alcohol 2. Here the coupling is depicted using EDC/DMAP/HOBt/THF, however, other suitable conditions may also be used. Depending on the nature of R4 and R5 an amino ketone may be used, in place of the amino alcohol, thus avoiding the subsequent oxidation step. In the case of fluoromethyl ketones where R5 is
CH2F, the amino alcohol 2 may be obtained according to the method of Revesz et al., Tetrahedron Lett . 1994, 35, 9693. In the case of tetrafluorophenoxy ketones where R5 is -CH20-2, 3, 5, 6-tetrafluorophenyl, amino alcohol 2 may be obtained by methods analogous to those of Semple et al . , Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1337 (Scheme II) .
[0051] Finally the hydroxy group in compound 3 is oxidized (e.g., with Dess-Martin periodinane) and the resulting compound treated appropriately according to the nature of R4. For example, in product I if R4 is a carboxylic acid, then R4 in 3 is preferably an ester that is hydrolyzed in the final step of the scheme. If that ester is a t-butyl ester (i.e., if R4 is Cθ2tBu) , treatment -with trifluoroacetic acid will give the acid. The ester is preferably a t-butyl ester when the other substituents in I are compatible with acidic conditions . [0052] If R4 in product I is an ester, the desired ester may be prepared by esterifying the corresponding acid or by having the desired ester group already present in compound 2.
Scheme II
Figure imgf000024_0001
Scheme II (a) KF/DMF/ArOH; (b) NaBH4/THF ; ( c ) H2 /Pd/C/MeOH
[0053] In scheme II above, the following abreviations are used: KF is potassium fluoride; DMF is N,N- dimethylformamide; ArOH is 2, 3 , 5, 6-tetrafluorophenol; THF is tetahydrofuran; MeOH is methanol. Commercially available bromoketone 4 (R=C02 Bu) is reacted with 2, 3 , 5, 6-tetrafluorophenol and potassium fluoride to give phenoxy ketone 5. The ketone is then reduced with, for example, sodium borohydride to give the alcohol 6, which is hydrogenated by using, for example, palladium on carbon as catalyst to give the amino alcohol 2 (R= C02tBu, R5= CH20-2, 3, 5, 6-tetrafluorophenyl) . Scheme III
Figure imgf000025_0001
Scheme III (a)H2 Pd/C MeOH; (b) PhCH20(CO)Cl/Na2C03/H20/THF; (c) (CF3S02)20 / 2,6-
Lutidine/DCM; (d) NaH/THF; (e) Rl-Cl/Et3N/DMAP/DCM; (f)
TFA/DCM
[0054] In Scheme III the folowing abreviatons are used: Z is a benzyloxycarbonyl protecting group; MeOH is methanol; DCM is dichloromethane; TFA is trifluoroacetic acid; DMAP is 4-dimethylaminopyridine; THF is tetrahydrofuran. Pyridone acid derivatives I can be prepared in chiral form using the synthetic sequence shown in Scheme III. The starting (2-oxo-l, 2-dihydro- pyridin-3-yl) -carbamic acid benzyl ester (R2=H) is prepared using a procedure similar to that described by Warner et al J. Med. Chem. 1994, 37(19), 3090-3099 Commercially available (R) -fcerfc-butyl-2-hydroxybutyrate (R3=ethyl) is treated with trifluoromethanesulphonic anhydride and 2,6-lutidine in DCM to give the corresponding triflate. Reaction of the tri late with the anion of (2-oxo-l, 2-dihydro-pyridin-3-yl) -carbamic acid benzyl ester (prepared by deprotonation with sodium hydride in THF) gives the N-alkylated pyridone. Removal of the benzyloxycarbonyl protecting group using hydrogen and palladium on carbon gives the amine. This is then reacted with an appropriate electrophile, triethylamine and DMAP in DCM. For example if R1 is required to be RC=0 (an amide) then an appropriately substituted acid chloride may be used. If R1 is required to be RS(=0)2 (sulphonamide) then an appropriately substituted sulfonyl chloride may be used. If R1 is RO(C=0) (carbamate) then an appropriately substituted chloroformate may be used. If R1 is RN(C=0) (urea) then an appropriately substituted carbamoyl chloride or isocyanate may be used. The other R1 groups may be prepared accordingly. Acid 1 is then prepared by deprotection of the ester by, for example, using trifluoroacetic acid. The acid is then coupled to amino alcohol 2 (Scheme 1) .
[0055] Therefore, another embodiment of this invention provides a process for preparing a compound of formula I:
Figure imgf000026_0001
(i) wherein R1, R2, R3, R4 and R5, are as defined in any of the embodiments herein, comprising:
(a) reacting a compound of formula (III) :
Figure imgf000026_0002
wherein:
R9 is -N02, -C(0)0R10, R6C(0)N(H)-, R6S02N(H)-,
R50C(0)N(H)-, (R6)2NC(0)N(H)-, R6C (0) C (0) N (H) - , R6N(H)-, (R6)2NC(0)C(0)N(H)-, or R6OC (0) C (O)N(H) - ; * R10 is independently hydrogen, (C1-C12) -aliphatic- (C3- C10) -cycloaliphatic-, (C6-C10) -aryl-, (C3-C10)- heterocyclyl-, (C5-C10) -heteroaryl-, (C3-C10)- cycloaliphatic- (C1-C12) -aliphatic-, (C6-C10) -aryl- (Cl- C12) -aliphatic-, (C3-C10) -heterocyclyl- (C1-C12) - aliphatic-, (C5-C10) -heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N(H) , N(R) , S, SO, and S0 ; and wherein R10 is optionally substituted with up to 6 substituents independently selected from R; and R, R2, R3 and R6 are as defined in any of the embodiments of formula (I) herein; with a compound of formula (IV) :
Figure imgf000027_0001
(IV) wherein Y is either a carbonyl group or an OH group; and
R4 and R5 are as defined in any of the embodiments of formula (I) herein; in the presence of peptide coupling conditions and a solvent; provided that if Y is an OH group, then the process further comprises (b) oxidizing the OH group to provide the compound of formula (I) ; and provided that if R9 is -N02, -C(0)0R10, or -CN, the process comprises the further step of converting the -N02, -C(0)0R10, or -CN into R6C(0)N(H)-, R6S02N(H)-, R6OC(0)N(H)-, (R5)2NC(0)N(H)-, R6C (0) C (O)N(H) -, R6N(H)- (R6)2NC(0)C(0)N(H)-, or R6OC (0) C (O)N(H) - . [0056] The coupling conditions may be any known to skilled practitioners for forming peptidyl bonds. Preferred coupling conditions are EDC/DMAP/HOBt . A preferred solvent in the above embodiment is THF. [0057] In a preferred embodiment, the compound of formula (III) :
Figure imgf000028_0001
(III) wherein R2, R3, and R9 are as defined herein; is prepared by a process comprising: (c) reacting a compound of formula (V) :
Figure imgf000028_0002
(V) wherein R, R2, R3, and R9 are as defined herein; in a solvent in the presence of deprotecting conditions . [0058] The deprotecting conditions will depend on the specific protecting group (i.e., R10) . For example, if R10 is t-butyl, then preferred deprotecting conditions would include acid hydrolysis. A preferred acid is TFA. A' preferred solvent is DCM. More preferably the solvent and the hydrolyzing conditions comprise TFA and DCM. If R10 is methyl or ethyl, then preferred deprotecting conditions would be basic (e.g., aqueous NaOH). If R10 is benzyl , then the benzyl group could be removed by hydrogenolysis .
[0059] In a preferred embodiment, the compound of formula (V) :
Figure imgf000029_0001
(V) wherein R2, R3, R9, and R10 are as defined herein; is prepared by a process comprising: (d) reacting a compound of formula (VI) :
Figure imgf000029_0002
(VI) wherein R2 and R9 are as defined herein; with a compound of formula (VII) :
Figure imgf000029_0003
(VII) wherein X is a suitable leaving group; and R3 and R10 are as defined herein; in the presence of a solvent and a base. [0060] Preferably, X is -I, -Br, -Cl, -OH, an alkylsulfonate, or an aryl sulfonate. When X is -OH, an appropriate leaving group may be generated in situ (e.g., as in the Mitsunobu reaction) . Preferred sulfonates include -O-trifluoromethanesulfonate, -0- methanesulfonate, -O-benzenesulfonate, -O-p- toluenesulfonate, -O-m-nitrobenzenesulfonate, and -0-p- nitrobenzenesulfonate. Suitable leaving groups useful in the methods of this invention are well known in the art. See, e.g., "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J. , John Wiley & Sons, New York (2001) .
[0061] Any solvent that is compatible with the generation of anions may be used. Preferred solvents include DMF, toluene, and THF. [0062] Suitable bases include any that may remove a proton from the hydroxy group in (V) . Such bases include BuLi, LDA, LHMDS, and NaH. Preferably, the base is NaH. [0063] Another embodiment of this invention provides a process for preparing a compound of formula (VIII) :
Figure imgf000030_0001
(VIII) wherein:
R2 is -CF3, -CI, -OR7, -N02, -OCF3, -CN, or R8; and
R3, R8, R9, and R10 are as defined herein; comprising the step of (e) reacting a compound of formula (IX) :
Figure imgf000031_0001
( IX) wherein R2 and R9 are as defined herein; with a compound of formula (VII ) :
O X :. ORιo
FT
(VII) wherein R3 and R10 are as defined herein; and X is a suitable leaving group; in the presence of a solvent and a base. [0064] Preferably, X is -I, -Br, -Cl, -OH, an alkylsulfonate, or an aryl sulfonate. When X is -OH, an appropriate leaving group may be generated in situ (e.g., as in the Mitsunobu reaction) . Preferred sulfonates include -0-trifluoromethanesulfonate, -0- methanesulfonate, -O-benzenesulfonate, -O-p- toluenesulfonate, -O-m-nitrobenzenesulfonate, and -O-p- nitrobenzenesulfonate .
[0065] Any solvent is compatible with the generation of anions may be used. Such solvents include DMF, toluene, and THF. Preferably, the solvent is THF.
[0066] Suitable bases include any that may remove a proton from the hydroxy group in (V) . Such bases include BuLi, LDA, LHMDS, and NaH. Preferably, the base is NaH. [0067] Another embodiment of this invention provides a process for preparing a compound of formula (I) :
Figure imgf000032_0001
(i) wherein R1, R2, R3, R4, and R5, are as defined in any of the embodiments herein, comprising: (a) reacting a compound of formula (VI or IX) :
Figure imgf000032_0002
wherein:
R9 is -N02, -C(0)0R 10 -CN, R6C(0)N(H)-, R6S02N(H)
R6OC(0)N(H)-, (R6)2NC(0)N(H)-, R5C (O) C (0) N (H) - , R6N(H)-, (R6)2NC(0)C(0)N(H)-, or R6OC (0) C (O)N(H) -; and
R2, R3 and R6 are as defined herein; with a compound of formula (X) :
Figure imgf000032_0003
(X) wherein Y is either a carbonyl group or an OH group; and R4 and R5 are as defined herein; in the presence of any of the coupling conditions defined herein and a solvent; provided that if Y is an OH group, then the process further comprises (b) oxidizing the OH group to provide the compound of formula (I) ; and provided that if R9 is -N02, -C(0)OR10, or -CN, the process comprises the further step of converting the -N02, -C(0)0R10, or -CN into R6C(0)N(H)-, R6S02N(H)-, R60C(0)N(H)-, (R5)2NC(0)N(H)-, R6C (0) C (O)N(H) -, R6N(H)-, (Rs)2NC(0)C(0)N(H)-, or R5OC (0) C (O)N(H) - . [0068] The compounds of this invention can be assayed for their, ability to inhibit the release of IL-lβ, caspase activity, or apoptosis directly. Assays for each of the activities are known in the art. Selected assays are described below. [0069] If pharmaceutically acceptable salts of the compounds of this invention are utilized in these compositions, those salts are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl- propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts,
N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
[0070] Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others . Water or oil-soluble or dispersible products are thereby obtained. [0071] The compounds utilized in the compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
[0072] Pharmaceutically acceptable carriers that may be used in these compositions include, but are not limited to, ion exchangers, 'alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers , polyethylene glycol and wool fat. [0073] According to a preferred embodiment, the compositions of this invention are formulated for pharmaceutical administration to a mammal, preferably a human being . [0074] Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally or intravenously. [0075] Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents . The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol . Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
[0076] The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added. [0077] Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable 'non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols . [0078] The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs . [0079] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
[0080] For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers . Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[0081] For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum. [0082] The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons , and/or other conventional solubilizing or dispersing agents .
[0083] The above-described compositions are particularly useful in therapeutic applications relating to an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, or various forms of liver disease. Such diseases include those related to rheumatology and autoimmunity, such as rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, myasthenia gravis, autoimmune neutropenia, autoimmune hemolytic anemia, thrombocytopenia, juvenile rheumatoid arthritis, gout, Behcet's syndrome, Still's syndrome, macrophage activation syndrome, and sarcoidosis; auto-inflammatory syndromes, such as cryopyrin-associated Periodic Syndromes, (including Muckle-Wells syndrome, familial cold urticaria, chronic infantile neurological cutaneous and articular syndrome (a.k.a. neonatal onset multisystem inflammatory disease) ) , familial mediterranean fever, TNFRl-Associated Periodic Syndrome (TRAPS) , Hyper-IgD periodic fever Syndrome (HIDS), and Blau's syndrome; dermatology, such as psoriasis, atopic dermatitis, scarring, alopecia, acne vulgaris, and pemphigus; respiratory, such as asthma, adult respiratory distress syndrome, cystic fibrosis, emphysema, chronic bronchitis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis; internal medicine, such as inflammatory peritonitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, autoimmune gastritis, H.pylori-associated gastric and duodenal ulcer disease, diabetes, pancreatitis, glomerulonephritis, chronic active hepatitis, excess dietary alcohol intake disease, renal disease, polycystic kidney disease, burns, organ apoptosis after burn injury, haemorrhagic shock, organ failure (e.g., hepatic failure, acute renal failure, and acute respiratory failure) , and endometriosis; transplants, such as graft vs. host disease (GVHD) and organ transplant rejection; oncology, such as leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, and multiple myeloma; cardiovascular, such as chronic heart disease, acute heart disease, myocardial infarction, myocardial ischemia, congestive heart failure, atherosclerosis, coronary artery bypass graft (CABG) , and acute coronary syndrome; the central and peripheral nervous systems, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV- related encephalitis, traumatic brain injury, spinal cord injury, neurological damage due to stroke, diabetic neuropathy, and acute and chronic pain; ophthalomology, such as uveitis, retinal disorders, diabetic retinopathy, glaucoma, and keratitis; infectious diseases, such as viral mediated disease, sepsis, septic shock, Shigellosis, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, Japanese encephalitis, HIV infection, tuberculosis, meningitis, Pseudomonas infection, and Acinetobacter infection; and other diseases, such as aging. The compounds and compositions are also useful in treating complications associated with coronary artery bypass grafts . The amount of compound present in the above-described compositions should be sufficient to cause a detectable decrease in the severity of the disease or in caspase activity and/or cell apoptosis, as measured by any of the assays known in the art.
[0084] According to another embodiment, the compositions of this invention may further comprise another therapeutic agent. Such agents include, but are not limited to, thrombolytic agents such as tissue plasminogen activator and streptokinase. When a second agent is used, the second agent may be administered either as a separate dosage form or as part of a single dosage form with the compounds or compositions of this invention. Accordingly, a combined preparation for simultaneous, separate, or sequential use is provided by this invention.
[0085] Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of a disease involving caspase activity and/or apoptosis. [0086] Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w) . Preferably, such preparations contain from about 20% to about 80% active compound. [0087] When the compositions of this invention comprise a combination of a compound of formula I and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen. [0088] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredients will also depend upon the particular compound and other therapeutic agent, if present, in the composition. [0089] In a preferred embodiment, the invention provides a method of treating a mammal, having one of the aforementioned diseases, comprising the step of administering to said mammal a pharmaceutically acceptable composition described above. In this embodiment, if the patient is also administered another therapeutic agent or caspase inhibitor, it may be delivered together with the compound of this invention in a single dosage form, or, as a separate dosage form. When administered as a separate dosage form, the other caspase inhibitor or agent may be administered prior to, at the same time as, or following administration of a pharmaceutically acceptable composition comprising a compound of this invention. [0090] In order that this invention be more fully understood, the following preparative and testing examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way. Example 1
(S, S) -3- [2- (3-Acetylamino-2-oxo-2iϊ-pyridin-l-yl) - butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000042_0001
Method A:
(S) -2- (3-Benzyloxycarbonylamino-2-oxo~2.H-pyridin-l-yi; butyric acid tert-butyl ester
Figure imgf000043_0001
[0091] To a cooled (0°C) solution of (R) -tert-butyl hydroxybutyrate (1.03 g, 6.43 mmol) in dichloromethane (25 mL) , was slowly added 2,6-lutidine (1.38 g, 12.9 mmol) and then trifluoromethanesulfonic anhydride (3.45 g, 12.2 mmol) . The resulting mixture was stirred at 0°C for 1 hour, then partitioned between tert-butylmethyl ether (150 mL) and an aqueous solution of IM HCl (30 mL) . The organic layer was washed with brine (30 mL) , dried (sodium sulfate) , filtered and concentrated to afford the triflate as a light brown oil.
[0092] To a solution of (2-oxo-l, 2-dihydro-pyridin-3- yl) -carbamic acid benzyl ester (P. Warner et al . , J. Med. Chem. , 37, 19, 1994, 3090-3099) (1.73 g, 7.07 mmol) in dry THF (60 mL) was added sodium hydride (60% dispersion, 257 mg, 6.43 mmol) and the solution was stirred at room temperature for 45 minutes. The reaction mixture was then slowly transferred with a canula onto a solution of the triflate prepared above in THF (3 mL) . The reaction mixture was stirred at room temperature for 90 minutes and quenched with aqueous ammonium chloride (10 mL) . Most of the solvent was evaporated and the residue was partitioned between EtOAc and saturated aqueous NHC1. The organic layer was washed with brine (30 mL) , dried (MgS0) , filtered and evaporated. The residue was purified by flash chromatography (10% ethyl acetate/hexane) to afford the title compound as a colourless oil (2.48 g, 100%): 1H NMR (400 MHz, CDC13) δ 0.92 (3H, t), 1.45(9H, s) , 1.94(1H, m) , 2.25(lH, m) , 5.23 (2H, s), 5.47 (IH, dd) , 6.32 (IH, t) , 7.01 (IH, d) , 7.32- 7.43 (5H, m) , 7.92 (IH, s) , 8.06 (IH, br d) . Method B:
(S) -2- (3-Amino-2-oxo-2Jϊ-pyridin-l-yl) -butyric acid tert- butyl ester
Figure imgf000044_0001
[0093] To a solution of (S)-2-(3- Benzyloxycarbonylamino-2-oxo-2iϊ-pyridin-l-yl) -butyric acid tert-butyl ester (2.48 g, 6.43 mmol) in a mixture of MeOH (15 mL) and EtOAc (15 mL) was added 10% Pd/C (250 mg) . The mixture was degassed and stirred at room temperature for 90 minutes under an atmosphere of hydrogen (balloon pressure) . The reaction mixture was filtered through a short pad of silica which was then flushed with MeOH. The combined filtrates were evaporated under reduced pressure to afford the title compound as a white solid (1.62 g, 100%); 1H NMR (400 MHz, CDC13) δ 0.91 (3H, t), 1.44(9H, s) , 1.91(1H, m) , 2.21(1H, m) , 4.24 (2H, br s) , 5.50 (IH, dd) , 6.11 (IH, t) , 6.53 (IH, d) , 6.77 (IH, d) . 'Method C: (S) -2- (3-Acetylamino-2-oxo-2.ϊ-pyridin-l-yl) -butyric acid terfc-butyl ester
Figure imgf000044_0002
[0094] To a cooled (0°C) solution of (S) -2- (3-Amino-2- oxo-2iϊ-pyridin-l-yl) -butyric acid tert-butyl ester (500 mg, 1.98 mmol) in dichloromethane (5 mL) was added triethylamine (220 mg, 2.18 mmol) followed by acetic anhydride (202 mg, 1.98 mmol) . The reaction mixture was stirred at room temperature for 12 hours and then partitioned between EtOAc and aqueous IM HCl. The organic layer was washed with saturated aqueous NaHC03, brine (30 mL) , dried (MgS04) , filtered and evaporated. The residue was purified by flash chromatography (40% ethyl acetate/hexane) to afford the title compound as a colourless oil (569 mg, 97%) : 1H NMR (400 MHz, CDCl3) δ 0.87 (3H, t), 1.40(9H, s) , 1.91(1H, ) , 2.13 (3H, s) , 2.19(1H, m) , 5.38 (IH, dd) , 6.26 (IH, t) , 6.99 (IH, d) , 8.33 (IH, d) , 8.43 (IH, br s) . Method D: (S) -2- (3-Acetylamino-2-oxo-2H-pyridin-l-yl) -butyric acid
Figure imgf000045_0001
[0095] A solution of (S) -2- (3-Acetylamino-2-oxo-2J:f- pyridin-1-yl) -butyric acid tert-butyl ester (569 mg, 1.93 mmol) in dichloromethane (5 mL) was cooled to 0°C. Trifluoroacetic acid (5 ml) was added and the resulting mixture allowed to warm to room temperature and stir for 2 hours. The mixture was then concentrated under reduced pressure and the residue redisolved in dichloromethane. This process was repeated several times in order to remove excess trifluoroacetic acid. The resulting solid was slurried in diethyl ether, filtered and washed with more diethyl ether. The solid was then dried to constant weight under vacuum. This gave the title product as a white solid (327 mg, 71%); 1H NMR (400 MHz, d6-DMS0) δ 0.78 (3H, t), 2.02-2.17 (5H, m) , 4.98 (IH, dd) , 6.29 (IH, t), 7.35 (IH, d) , 8.21 (IH, d) , 9.30 (IH, s), 13.07 (IH, vbr s) . Method E:
(S, S) -3- [2- (3-Acetylamino-2-oxo-2iϊ-pyridin-l-yl) - butyrylamino] -4-hydroxy-5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid , ert-butyl ester
Figure imgf000046_0001
[0096] A stirred mixture of (S) -2- (3-Acetylamino-2- oxo-2ϊ-pyridin-l-yl) -butyric acid (100 mg, 0.42 mmol), 3- amino-5- (2,3,5, 6-tetrafluorophenoxy) -4-hydroxy-pentanoic acid tert-butyl ester (163 mg, 0.462 mmol), HOBt (62 mg, 0.462 mmol), DMAP (56 mg, 0.462 mmol) and THF (5 mL) was cooled to 0°C then EDC (89 mg, 0.462 mmol) was added. The mixture was allowed to warm to room temperature during 16h then concentrated under reduced pressure. The. residue was purified by flash chromatography (50-50% ethyl acetate/hexane) to afford the title compound as a white foam (221 mg, 92%); 1H NMR (400 MHz, CDC13) δ 0.88- 0.93 (3H, m) , 1.37-1.38 (9H, 2s), 1.86-1.96 (IH, m) , 2.15-2.25 (4H, ) , 2.55-2.71 (2H, m) , 3.70-4.64 (5H, m) , 5.30-5.39 (IH, m) , 6.30-6.35 (IH, m) , 6.75-6.86 (IH, m) , 7.17-7.31 (2H, m) , 8.31-8.47 (2H, m) . Method F:
(S, S) -3- [2- (3-Acetylamino-2-oxo-2H-pyridin-l-yl) - butyrylamino] -4-oxo-5- (2,3,5, 6-tetra luoro-phenoxy) pentanoic acid tert-butyl ester
Figure imgf000047_0001
[0097] A stirred solution of (S, S) -3- [2- (3- Acetylamino-2-oxo-2iϊ-pyridin-l-yl) -butyrylamino]-4- hydroxy-5- (2,3,5, 6-tetrafluoro-phenoxy) -pentanoic acid tert-butyl ester (221 mg, 0.385 mmol) in anhydrous DCM (10 L) was treated with 1, 1, 1-triacetoxy-l, 1-dihydro- 1, 2-benziodoxol-3 (IH) -one (212 mg, 0.5 mmol) at 0°C. The resulting mixture was kept at 0°C for 2hr, diluted with ethyl acetate, then poured into a 1:1 mixture of saturated aqueous sodium hydrogen carbonate and saturated aqueous sodium thiosulfate. The organic layer was removed and the aqueous layer re-extracted with ethyl acetate. The combined organic extracts were dried (Magnesium sulfate) and concentrated. The residue was purified by flash chromatography .(50-50% ethyl acetate/hexane) to afford the title compound as a white solid (187 mg, 85%); Η NMR (400 MHz, CDC13) δ 0.93 (3H, t), 1.36 (3H, s), 1.95 (IH, m) , 2.21 (3H, s) , 2.25 (IH, m) , 2.73 (2H, dd) , 2.89 (IH, dd) , 4.91 (IH, m) , 5.04-5.17 (2H, ) , 5.47 (IH, m) , 6.34 (IH, t) , 6.80 (IH, m) , 7.19 (IH, m) , 7.68 (IH, d) , 8.36-8.41 (2H, m) . Method G:
(S, S) -3- [2- (3-Acetylamino-2-oxo-2H-pyridin-l-yl) - butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) pentanoic acid
Figure imgf000048_0001
[0098] A solution of (S, S) -3- [2- (3- cetylamino-2-oxo- 2.F--pyridin-l-yl) -butyrylamino] -4-oxo-5- (2,3,5,6- tetrafluoro-phenoxy) -pentanoic acid tert-butyl ester (187 mg, 0.327 mmol) in dichloromethane (5 mL) was cooled to 0°C. Trifluoroacetic acid (5 ml) was added and the resulting mixture allowed to warm to room temperature and stir for 2 hours . The mixture was then concentrated under reduced pressure and the residue redisolved in dichloromethane. This process was repeated several times in order to remove excess trifluoroacetic acid. The resulting solid was slurried in diethyl ether, filtered and washed with more diethyl ether. The solid was then dried to constant weight under vacuum. This gave the title product as a white solid (138 mg, 82%); NMR (400 MHz, d6-DMSO) δ 0.78 (3H, t) , 1.87-2.13 (5H, m) , 2.56-
2.78 (2H, ) , 4.62 (IH, ) , 5.18-5.29 (2H, m) , 5.40 (IH, m) , 6.28 (IH, t) , 7.37 (IH, d) , 7.53-7.66 (IH, m) , 8.17- 8.21 (IH, m) , 8.92 (IH, d) , 9.21 (IH, s), 12.51 (IH, br s) ; 19F NMR (376 MHz, d6-DMS0, proton-decoupled) δ -156.9, -141.1; M+H 516.2, M-H 514.2. Example 2 (S, S) - 4-0x0-3- [2- (2-oxo-3-propionylamino-2H-pyridin-l- yl) -butyrylamino] -5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000049_0001
[0099] Prepared from (S) -2- (3-Amino-2-oxo-2F-pyridin-
1-yl) -butyric acid tert-butyl ester and propionic anhydride according to methods C-G; white solid; IR
(solid) 1584, 1642, 1662, 1717, 1749 cm-1; NMR (400
MHz, d6-DMSO) δ 0.78 (3H, t) , 1.04 (3H, t) , 1.88-2.11 (2H, m) , 2.43 (2H, q) , 2.59 (IH, d) , 2.75 (IH, dd) , 4.61
(IH, m) , 5.18-5.29 (2H, 2dd) , 5.40 (IH, m) , 6.29 (IH, t) ,
7.37 (IH, d) , 7.58 (IH, ) , 8.22 (IH, d) , 8.91 (IH, d) ,
9.08 (IH, s), 12.50 (IH, br s) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -140.6, -140.8, -141.1, -156.8, -157.0; M+H 530.2, M-H 528.3.
Example 3
(S, S) - 3- [2- (3-Butyrylamino-2-oxo-2H-pyridin-l-yl) - butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000049_0002
[0100] Prepared from (S) -2- (3-Amino-2-oxo-2H-pyridin-
1-yl) -butyric acid tert-butyl ester and butyryl chloride according to methods C-G; beige solid; IR (solid) 1659, 1645, 1509, 1490 cm-1; 1H NMR (400 MHz, d6-DMSO) δ 0.76- 0.80 (3H, m) , 0.88 (3H, t) , 1.53-1.58 (2H, m) , 1.88-1.93
(IH, m) , 2.01-2.09 (IH, m) , 2.37-2.41 (2H, m) , 2.59 (IH, dd) , 2.70-2.81 (IH, m) , 4.59-4.63 (IH, m) , 5.20-5.25 (2H, m) , 5.38-5.50 (IH, 2 x m) , 7.36-7.38 (IH, m) , 7.55-7.61
(IH, m) , 8.21-8.23 (IH, m) , 8.61-8.92 (IH, 3 x d) , 9.06- 9.10 (IH, m) , 12.49 (IH, br s) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -140.6, -141.1, -156.9, -157.0; M+H 544.3, M-H 542.3. Example 4
(S, S) -3-{2- [3- (Cyclopropanecarbonyl-amino) -2-oxo-2H- pyridin-1-yl] -butyrylamino} -4 -oxo-5- (2,3,5, 6-tetraf luorophenoxy) -pentanoic acid
Figure imgf000050_0001
[0101] Prepared from (S) -2- (3-Amino-2-oxo-2iϊ-pyridin-
1-yl) -butyric acid tert-butyl ester and cyclopropanecarbonyl chloride according to methods C-G; white solid; NMR (400 MHz, d6-DMSO) δ 0.74-0.82 (7H, m) , 1.93 (IH, m) , 2.07 (IH, m) , 2.17 (IH, m) , 2.59 (IH, d) , 2.75 (IH, dd) , 4.62 (IH, m) , 5.19-5.30 (2H, 2dd) ,
5.41 (IH, m) , 6.27 (IH, t) , 7.37 (IH, d) , 7.57 (IH, m) ,
8.17 (IH, d) , 8.92 (IH, d) , 9.49 (IH, s) , 12.51 (IH, br s); M+H 542.2, M-H 540.3. Example 5
(S, S) - 3- [2- (3-Isobutyrylamino-2-oxo-2H-pyridin-l-yl) - butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) -pentanoic acid
Figure imgf000051_0001
[0102] Prepared from (S) -2- (3~Amino-2-oxo-2iϊ-pyridin- 1-yl) -butyric acid tert-butyl ester and isobutyryl chloride according to methods C-G; white solid; IR (solid) 1664, 1517, 1491 cm-1; 1H NMR (400 MHz, d6-DMSO) δ 1.75-1.85 (3H, m) , 1.05 (6H, d) , 1.9-2.1 (2H, ) , 2.6-2.9 (3H, m) , 4.55-4.62 (IH, m) , 5.2-5.35 (2H, m) , 5.4-5.43 (IH, m) , 6.25 (IH, t) , 7.4-7.45 (IH, m) , 7.6-7.7 (IH, ) , 8.2-8.24 (IH, m) , 8.8-9.0 (2H, m) ; M+H 544.3, M-H 542.3.
Example 6 (S, S) -3-{2- [3- (2-Methoxy- cetylamino) -2-oxo-2H-pyridin-l- yl] -butyrylamino} -4-oxo-5- (2,3,5, 6-tetrafluorophenoxy) -pentanoic acid
Figure imgf000051_0002
[0103] Prepared from (S) -2- (3-Amino-2-oxo-2H-pyridin- 1-yl) -butyric acid tert-butyl ester and methoxyacetyl chloride according to methods C-G; pink solid; Η NMR (400 MHz, d6-DMSO) δ 0.75-0.80 (3H, m) , 1.88-1.97 (IH, m) , 2.02-2.10 (IH, m) , 2.56-2.63 (IH, m) , 2.72-2.79 (IH, ) , 3.37-3.40 (3H, m) , 4.00-4.03 (2H, ) , 4.53-4.65 (IH, m) , 5.13-5.46 (3H, ) , 6.32-6.35 (IH, ) , 7.39-7.45 (IH, m) , 7.51-7.66 (IH, m) , 8.21-8.26 (IH, m) , 8.92-8.98 (IH, m) , 9.12-9.17 (IH, m) , 12.51 (IH, br s) ; M+H 546.2, M-H 544.2.
Example 7 (S, S) -3- (2-{3- [ (Furan-2-carbonyl) -amino] -2-oxo-2#- pyridin-1-yl} -butyrylamino) -4-oxo-5- (2,3,5, 6-tetrafluorophenoxy) -pentanoic acid
Figure imgf000052_0001
[0104] Prepared from (S) -2- (3-Amino-2-oxo-2H-pyridin- 1-yl) -butyric acid tert-butyl ester and 2-furoyl chloride according to methods C-G; white solid; 1H NMR (400 MHz, d6-DMSO) δ 0.81 (3H, m) , 1.95 (IH, m) , 2.09 (IH, m) , 2.60 (IH, dd) , 2.77 (IH, dd) , 4.61 (IH, m) , 5.19-5.29 (2H, m) , 5.42 (IH, m) , 6.39 (IH, t) , 6.74 (IH, m) , 7.30 (IH, m) , 7.46-7.58 (2H, m) , 7.95 (IH, m) , 8.27 (IH, d) , 8.98' (lHd) , 9.16 (IH, s) , 12.50 (IH, br s) ; M+H 568.3, M-H 566.3.
Example 8 (S,S)-3-(2-{3-[ (Furan-3-carbonyl) -amino] -2-oxo-2H- pyridin-1-yl} -butyrylamino) -4-oxo-5- (2,3,5, 6-tetrafluorophenoxy) -pentanoic acid
Figure imgf000053_0001
[0105] Prepared from (S) -2- (3-Amino-2-oxo-2H-pyridin- 1-yl) -butyric acid tert-butyl ester and 3-furoyl chloride according to methods C-G; off-white solid; IR (solid) 1748, 1711, 1663, 1640, 1583, 1517, 1488 cm-1; NMR (400 MHz, d6-DMS0) δ 0.80 (3H, m) , 1.90-2.20 (2H, m) , 2.60- 2.90 (2H, m) , 4.65 (IH, m) , 5.10-5.60 (3H, ) , 6.40 (IH, t), 6.95 (IH, m) , 7.40-7.65 (2H, m) , 7.85 (IH, s) , 8.20 (IH, m) , 8.50 (IH, m) , 8.90-9.20 (2H, m) ; 19F NMR (376 MHz, d6-DMS0, proton-decoupled) δ -141.0, -156.8; M+H 568.2, M-H 566.3.
Example 9 (S, S) -4-0x0-3- (2- {2-OXO-3- [ (pyridine-3-carbonyl) -amino] - 2i-f-pyridin-l-yl} -butyrylamino) -5- (2,3,5, 6-tetrafluoro- phenoxy) -pentanoic acid
Figure imgf000053_0002
[0106] Prepared from (S) -2- (3-Amino-2-oxo-2fl'-pyridin- 1-yl) -butyric acid tert-butyl ester and 3- pyridinecarbonyl chloride according to methods C-G
(isolated as a TFA salt); yellow solid; IR (solid) 1745, 1678, 1650, 1517, 1488; 1H NMR (400 MHz, d6-DMSO) δ 0.80 (3H, m) , 1.90-2.30 (2H, m) , 2.50-2.90 (2H, m) , 4.65 (IH, m) , 5.10-5.65 (3H, m) , 6.45 (IH, t) , 7.40-7.80 (3H, m) , 8.10-8.40 (2H, m) , 8.85 (IH, s) , 8.90-9.20 (2H, m) , 9.65 (IH, m) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -141.0, -156.8; M+H 579.2, M-H 577.3.
Example 10 (S, S) -3- (2- {3- [ (Isothiazole-3-carbonyl) -amino] -2-oxo-2ff- pyridin-1-yl} -butyrylamino) -4-oxo-5- (2,3,5,6- tetrafluorophenoxy) -pentanoic acid
Figure imgf000054_0001
[0107] Prepared from (S) -2- (3-Amino-2-oxo-2H-pyridin-
1-yl) -butyric acid tert-butyl ester and 3- isothiazolecarbonyl chloride according to methods C-G; pink solid; IR (solid) 1678, 1649, 1516, 1493 cm-1; NMR (400 MHz, d6-DMSO) δ 0.85 (3H, m) , 1.85-2.30 (2H, m) ,
2.50-2.90 (2H, m) , 4.20-4.70 (IH, 2m), 5.10-5.60 (3H, m) , 6.45 (IH, t), 7.40-7.70 (2H, m) , 7.95 (IH, m) , 8.40 (IH, d) , 8.95-9.15 (IH, 2m), 9.30 (IH, d) , 10.00 (IH, 2s); 19F NMR (376 MHz, d6-DMS0, proton-decoupled) δ -141.0, -156.9; M+H 585.1, M-H 583.2.
Example 11 (S, S) -3- [2- (3-Benzoylamino-2-oxo-2H-pyridin-l-yl) - butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000055_0001
[0108] Prepared from (S) -2- (3-Amino-2-oxo-2H-pyridin- 1-yl) -butyric acid tert-butyl ester and benzoyl chloride according to methods C-G; pink solid; IR (solid) 1645, 1509, 1490 cm-1; 1H NMR (400 MHz, d6-DMSO) δ 0.79-0.85 (3H, ) , 1.95-1.99 (IH, m) , 2.06-2.10 (IH, ) , 2.60 (IH, dd) , 2.77 ('IH, dd) , 4.59-4.63 (IH, m) , 5.25 (2H, m) , 5.42-5.55 (IH, m) , 6.38-6.42 (IH, m) , 7.51-7.62 (5H, ) , 7.89-7.91 (2H, m) , 8.27-8.31 (IH, ) , 8.69-8.99 (IH, m) , 9.28 (IH, m) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -140.6, -141.0, -156.9, -157.0; M+H 578.2, M-H 576.2.
Example 12 (S, S) -4-0x0-3- [2- (2-oxo-3-phenylacetylamino-2H-pyridin-l- yl) -butyrylamino] -5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000055_0002
[0109] Prepared from (S) -2- (3-Amino-2~oxo-2iϊ-pyridin- 1-yl) -butyric acid tert-butyl ester and phenylacetyl chloride according to methods C-G; pink solid; IR (solid) 1659, 1635, 1519 cm-1; NMR (400 MHz, d6-DMSO) δ 0.77
(3H, t) , 1.85-1.96 (IH, m) , 2.03-2.07 (IH, m) , 2.59 (IH, dd) , 2.71-2.77 (IH, m) , 3.79 (2H, s) , 4.61-4.66 (IH, ) , 5.16-5.29 (2H, m) , 5.35-5.44 (IH, m) , 6.28 (IH, t) , 7.24- 7.39 (6H, m) , 7.52-7.67 (IH, m) , 8.19-8.21 (IH, ) , 8.61- 8.92 (IH, ) , 9.28 (IH, br s) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -140.6, -141.0, -156.90, -157.0; M+H 592.2, M-H 590.2.
Example 13 (S, S) -3- [2- (3-Acetylamino-2-oxo-5-trifluoromethyl-2iϊ- pyridin-1-yl) -butyrylamino] -4 -oxo-5- (2,3,5, 6-tetraf luorophenoxy) -pentanoic acid
Figure imgf000056_0001
[0110] Prepared from (2-oxo-5-trifluoromethyl-1, 2- dihydro-pyridin-3-yl) -carbamic acid benzyl ester according to methods A-G; white solid; IR (solid) 1659, 1514 cm-1; NMR (400 MHz, d6-DMSO) δ 0.79 (3H, t) , 2.07- 2.33 (5H, m) , 2.59-2.79 (2H, m) , 4.59-4.63 (IH, m) , 5.18-
5.29 (2H, m) , 5.41-5.45 (IH, m) , 7.55-7.62 (IH, m) , 7.89
(IH, s), 8.41-8.43 (IH, ) , 9.04 (IH, d) , 9.61-9.63 (IH, m) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -61.4,
-140.7, -141.1, -156.8-156.9 -157.02, -157.1; M+H 584.2, M-H 582.2.
Example 14 (S, S) -3-{2- [3- (3-Ethyl-ureido) -2-oxo-2#-pyridin-l-yl] - butyrylamino} -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000057_0001
[0111] Prepared from (S) -2- (3-Amino-2-oxo-2iϊ-pyridin- 1-yl) -butyric acid tert-butyl ester and ethyl isocyanate according to methods C-G; pink solid; IR (solid) 1664, 1645, 1550, 1493, 1208 cm-1; 1H NMR (400 MHz, d6-DMSO) δ 0.80 (3H, t) , 1.05 (3H, t) , 1.80-2.20 (2H, m) , 2.50-2.85 (2H, m) , 3.15 (2H, m) , 4.65 (IH, m) , 5.25 (2H, dd) , 5.40 (IH, m) , 6.25 (IH, t) , 7.15 (IH, s) , 7.25 (IH, d) , 7.60 (IH, m) , 8.05 (IH, m) , 8.20 (IH, s) , 8.95 (IH, d) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -141.1, -156.9; M+H 545.2, M-H 543.2.
Example 15 (S, S) -3-{2- [3- (3, 3-Diethyl-ureido) -2-oxo-2H-pyridin-l- yl] -butyrylamino} -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000057_0002
Method H:
[0112] To a cooled (0°C) solution of (S) -2- (3-Amino-2- oxo-2H-pyridin-l-yl) -butyric acid tert-butyl ester (400 mg, 1.59 mmol) in dichloroethane (3 mL) was added triethylamine (0.254 mL, 1.82 mmol). This solution was added dropwise to a solution of diphosgene (0.11 mL, 0.91 mmol) in dichloroethane (7 mL) at 0°C over 10 minutes. The reaction mixture was stirred at room temperature for 90 minutes and then partitioned between EtOAc and aqueous
-5 IM HCl. The organic layer was washed with brine, dried (MgS04) , filtered and evaporated to afford the isocyanate as a brown oil.
[0113] To a cooled (0°C) solution of the isocyanate prepared above (244 mg, 0.79 mmol) in dichloroethane (4 0 mL) was added triethylamine (0.122 mL, 0.87 mmol) followed by diethylamine (0.082 mL, 0.79 mmol). The reaction mixture was stirred at room temperature for 3 hours and then partitioned between EtOAc and aqueous IM HCl. The organic layer was washed with brine, dried 5 (MgS04) , filtered and evaporated to afford a brown oily residue which was purified by flash column chromatography (50% ethyl acetate/hexane) to afford the diethylurea as a colourless oil. [0114] This intermediate was involved in the sequence 0 described in methods D-G to afford the title compound; pink solid; IR (solid) 1640, 1512, 1213 cm-1; 1H NMR (400 MHz, dδ-DMSO) 'δ 0.75-0.95 (3H, m) , 1.10-1.40 (6H, m) , 1.90-2.25 (2H, m) , 2.60-2.90 (2H, m) , 3.30-3.50 (4H, m) , 4.75 (IH, m) , 5.10-5.60 (3H, m) , 6.35 (IH, t) , 7.30 (IH, 5 m) , 7.75 (IH, m) , 7.80 (IH, m) , 8.05 (IH, m) , 8.95-9.05 (IH, m) ; 19F NMR (376 MHz, dδ-DMSO, proton-decoupled) δ -141.0, -156.9; M+H 573.3, M-H 571.2.
Example 16 (S, S) -4-OXO-3- (2-{2-oxo-3- [ (pyrrolidine-1-carbonyl) - 0 amino] -2iϊ-pyridin-l-yl} -butyrylamino) -5- (2,3,5,6- tetrafluoro-phenoxy) -pentanoic acid
Figure imgf000059_0001
[0115] Prepared from (S) -2- (3-Amino-2-oxo-2H-pyridin- 1-yl) -butyric acid tert-butyl ester and pyrrolidine according to methods H, D-G; pink solid; IR (solid) 1650, 1593, 1512, 1489, 1208 cm-1; 1H NMR (400 MHz, dδ-DMSO) δ 0.80 (3H, m) , 1.80-2.20 (6H, m) , 2.60-2.90 (2H, m) , 3.30- 3.50 (4H, m) , 4.60-4.75 (IH, m) , 5.10-5.50 (3H, m) , 6.30 (IH, t) , 7.35 (IH, m) , 7.50-7.75 (2H, m) , 8.00 (IH, ) , 8.85-8.95 (IH, m) ; 19F NMR (376 MHz, dδ-DMSO, proton- decoupled) δ -141.1, -156.9; M+H 571.3, M-H 569.3.
Example 17 (S, S) -3- [2- (3-Methoxycarbonylamino-2-oxo-2H-pyridin-l- yl) -butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000059_0002
[0116] Prepared from (S) -2- (3-Amino-2-oxo-2H-pyridin-
1-yl) -butyric acid tert-butyl ester and methyl chloroformate according to methods C-G; pink solid; IR
(solid) 1644, 1661, 1709 cm-1; Η NMR (400 MHz, d6-DMSO) δ 0.81 (3H, m) , 1.95 (IH, m) , 2.09 (IH, m) , 2.50-2.98 (2H, m) , 3.70 (3H, s) , 4.20-5.50 (4H, ) , 6.31 (IH, m) , 7.40
(IH, m) , 7.59 (IH, m) , 7.82 (IH, m) , 8.20 (IH, s) , 8.55- 9.00 (IH, d) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -140.6, -141.0, -141.1, -156.80, -156.9, -157.0, -157.1; M+H 532.3, M-H 530.3.
Example 18 (S, S) -3- [2- (3-Ethanesulfonylamino-2-oxo-2H'-pyridin-l-yl) - butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000060_0001
[0117] Prepared from (S) -2- (3-Amino-2-oxo-2 -pyridin- 1-yl) -butyric acid tert-butyl ester and ethanesulfonyl chloride according to methods C-G; pink solid; 1H NMR (400 MHz, d6-DMSO) δ 0.74-0.82 (3H, m) , 1.17-1.25 (3H, m) , 1.85-2.10 (2H, m) , 2.54-2.79 (2H, m) , 3.09-3.15 (2H, m) ,
4.58-4.68 (IH, m) 5.13-5.38 (2H, m) , 6.26-6.31 (IH, m) ,
7.34-7.38 (IH, m) 7.51-7.73 (2H, m) , 8.72-8.76 (IH, m) ,
8.89-8.97 (IH, m) 12.51 (IH, br s) ; M+H 566.2, M-H 564.2.
Example 19
(S, S) -4-Oxo-3-{2- [2-oxo-3- (propane-1-sulfonylamino) -2H- pyridin-1-yl] -butyrylamino} -5- (2,3,5, 6-tetrafluorophenoxy) -pentanoic acid
Figure imgf000060_0002
[0118] Prepared from (S) -2- (3-Amino-2-oxo-2H-pyridin- 1-yl) -butyric acid tert-butyl ester and propanesulfonyl chloride according to methods C-G; pink solid; 1H NMR (400 MHz, d6-DMSO) δ 0.74-0.82 (3H, m) , 0.88-0.94 (3H, m) , 1.63-1.74 (2H, m) , 1.85-2.10 (2H, m) , 2.56-2.79 (2H, m) , 3.06-3.13 (2H, m) , 4.58-4.68 (IH, m) , 5.13-5.40 (2H, m) , 6.26-6.31 (IH, m) , 7.34-7.37 (IH, m) , 7.50-7.62 (2H, m) , 8.71-8.75 (IH, m) , 8.90-8.97 (IH, m) , 12.53 (IH, br s) ; M+H 580.3, M-H 578.3. Example 20
(S, S) -4-0x0-3- {2- [2-oxo-3- (propane-2-sulfonylamino) -2H- pyridin-1-yl] -butyrylamino} -5- (2,3,5, 6-tetrafluorophenoxy) -pentanoic acid
Figure imgf000061_0001
[0119] Prepared from (S) -2- (3-Amino-2-oxo-2Jϊ-pyridin- 1-yl) -butyric acid tert-butyl ester and isopropylsulfonyl chloride using methods similar to C-G; pink solid; IR (solid) 1645, 1518 cm-1; 1H NMR (400 MHz, d6-DMS0) δ 1.7- 1.8 (3H, m) , 1.18-1.25 (6H, m) , 1.85-2.05 (2H, m) , 2.55- 2.8 (2H, m) , 3.2-3.3 (IH, m) , 4.52-4.62 (IH, m) , 5.15- 5.32 (3H, m) , 5.4-5.43 (IH, m) , 6.25 (IH, t) , 7.3-7.35 (IH, m) , 7.45-7.6 (2H, m) , 8.6-8.7 (IH, m) , 8.9-9.0 (IH, m) ; M+H 580.2, M-H 578.2.
Example 21 (S, S) -3- [2- (3-Benzenesulfonylamino-2-oxo-2.ϊ-pyridin-l- yl) -butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000062_0001
[0120] Prepared from (S) -2- (3-Amino-2-oxo-2i-f-pyridin- 1-yl) -butyric acid tert-butyl ester and benzenesulfonyl chloride according to methods C-G; pink solid; 1H NMR (400 MHz, d6-DMSO) δ 0.55-0.66 (3H, m) , 1.72-1.84 (IH, m) , 1.91-2.01 (IH, ) , 2.53-2.61 (IH, m) , 2.68-2.76 (IH, m) , 4.54-4.63 (IH, m) , 5.06-5.32 (2H, m) , 6.20-6.25 (IH, m) , 6.98-7.86 (9H, m) , 8.84-8.90 (IH, m) , 9.40-9.45 (IH, m) , 12.51 (IH, br s) ; M+H 614.1, M-H 612.1.
Example 22 (S, S) -3- [2- (3-Ethanesulfonylamino-2-oxo-5- trifluoromethyl-2-ϊ-pyridin-l-yl) -butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluoro-phenoxy) -pentanoic acid
Figure imgf000062_0002
[0121] Prepared from (2-oxo-5-trifluoromethyl-1, 2- dihydro-pyridin-3-yl) -carbamic acid benzyl ester according to methods A-G; off-white solid; IR (solid) 1664, 1519 cm-1; 1H NMR (400 MHz, d6-DMSO) δ 0.78-0.87 (3H, m) , 1.18-1.23 (3H, m) , 1.99-2.14 (2H, m) , 2.55-2.80 (2H, m) , 3.19-3.25 (2H, m) , 4.54-4.66 (IH, m) , 5.20-5.30 (2H, m) , 5.35-5.45 (IH, m) , 7.47 (IH, m) , 7.55-7.71 (IH, m) , 8.01 (IH, s), 9.05 (IH, m) , 9.31 (IH, s) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -63.11, -139.6, -157.1, -157.2; M+H 634.1, M-H 632.1.
Example 23 (S, S) -3- [3-Methyl-2- (2-oxo-3-phenylacetylamino-2iϊ- pyridin-1-yl) -butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluorophenoxy) -pentanoic acid
Figure imgf000063_0001
[0122] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) - carbamic acid benzyl ester according to methods A-G; .pink solid; IR (solid) 1644, 1683, 1740, 1791 cm-1; 1H NMR (400
MHz, dδ-DMSO) δ 0.6 (3H, m) , 1.0 (3H, m) , 2.2-2.3 (IH, m) , 2.5-3.0 (2H, m) , 3.7-3.8 (2H, m) , 4.1-5.4 (4H, m) ,
6.2-6.3 (IH, m) , 7.2-7.4 (5H, m) , 7.5-7.7 (2H, m) , 8.1-
8.2 (IH, m) , 8.7-9.2 (2H, m) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -140.6, -141.0, -156.8, -157.0,
-157.2; M+H 606.3, M-H 604.3.
Example 24
(S, S) -3- [2- (3-Ethanesulfonylamino-2-oxo-2H-pyridin-l-yl) -
3-methyl-butyrylamino] -4-oxo-5- (2,3,5, 6-tetrafluoro- phenoxy) -pentanoic acid
Figure imgf000063_0002
[0123] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) - carbamic acid benzyl ester according to methods A-G; off- white solid; IR (solid) 1595, 1646, 1682, 1742, 1789 cm-1; NMR (400 MHz, d6-DMSO) δ 0.7 (3H, m) , 0.9-1.0 (3H, m) , 1.2 (3H, m) , 2.3 (IH, m) , 2.6-3.0 (2H, m) , 3.1 (2H, ) , 4.1-5.4 (4H, ) , 6.3 (IH, m) , 7.3 (IH, m) , 7.5-7.7 (2H, m) , 8.7-9.2 (2H, m) ; 19F NMR (376 MHz, d6-DMSO, proton- decoupled) δ -140.6, -141.0, -156.7, -157.0, -157.1; M+H 580.2, M-H 578.3.
Example 25 (S) -5-Fluoro-4-oxo-3- [2- (2-oxo-3-propionylamino-2iϊ- pyridin-1-yl) -propionylamino] -pentanoic acid
Figure imgf000064_0001
[0124] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) - carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; pink solid; IR (solid) 1643, 1658, 1711,
1740 cm-1; NMR (400 MHz, d6-DMSO) δ 1.0-1.2 (3H, m) , 1.4-1.6 (3H, m) , 2.4-3.2 (4H, m) , 4.2-4.6 (1.5H, m) , 5.0- 5.6 (2.5H, m) , 6.3 (IH, m) , 7.3 (IH, m) , 8.2 (IH, m) , 8.3-8.8 ( IH, m) , 9.1 (IH, m) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -226.8, -226.9, -230.6, -231.4,
-232.7, -232.8; M+H 370.4, M-H 368.3.
Example 26
(S) -3- [2- (3-Benzoylamino-2-oxo-2-ϊ-pyridin-l-yl) - propionylamino] -5-fluoro-4-oxo-pentanoic acid
Figure imgf000064_0002
[0125] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; pink solid; IR (solid) 1523, 1644 cm-1; "Η NMR (400 MHz, d6-DMSO) δ 1.6 (3H, m) , 2.5-3.2 (2H, ) , 4.2-4.7 (1.5H, m) , 5.0-5.6 (2.5H, m) , 6.4* (IH, m) , 7.4- 7.6 (3H, m) , 7.9 (2H, m) , 8.3 (IH, m) , 8.5-8.9 (IH, m) , 9.3 (IH, ) ; 19F NMR (376 MHz, d6-DMS0, proton-decoupled) δ -226.7, -226.8, -230.4, -231.3, -232.8, -232.9; M+H 418.3, M-H 416.3.
Example 27 (S) -3-{2- [3- (2, 6-Dichloro-benzoylamino) -2-oxo-2iT-pyridin-
1-yl] -propionylamino}-5-fluoro-4-oxo-pentanoic acid
Figure imgf000065_0001
[0126] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) - carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; pink solid; IR (solid) 1521, 1646 cm-1; 1H NMR (400 MHz, d6-DMSO) δ 1.5-1.6 (3H, m) , 2.5-3.2 (2H, m) , 4.2-4.7 (1.5H, m) , 5.0-5.5 (2.5H, m) , 6.3-6.4 (IH, m) , 7.4-7.5 (3H, m) , 8.3 (IH, m) , 8.5-8.9 (IH, m) , 10.2 (IH, m) ; 19F NMR (376 MHz, dδ-DMSO, proton-decoupled) δ -226.7, -226.8, -230.6, -231.4, -232.8, -232.9; M+H 486.3, M-H 484.3.
Example 28 (S) -5-Fluoro-4-oxo-3- [2- (2-oxo-3-phenylacetylamino-2.H'- pyridin-1-yl) -propionylamino] -pentanoic acid
Figure imgf000066_0001
[0127] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) - carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; pink solid; IR (solid) 1524.2, 1652.4 cm-1;
Η NMR (400 MHz, d6-DMSO) δ 1.5 (3H, m) , 2.5-3.2 (2H, m) ,
3.8 (2H, m) , 4.2-4.7 (1.5H, m) , 5.0-5\5 (2.5H, m) , 6.3
(IH, m) , 7.2-7.4 (6H, m) , 8.2 (IH, m) , 8.4-8.9 (IH, m) , 9.3 (IH, m) ; 19F NMR (376 MHz,d6-DMSO, proton-decoupled) δ
-226.7, -226.8, -230.6, -231.5, -232.8, -232.9; M+H
432.3, M-H 430.3.
Example 29
(S) -5-Fluoro-4-oxo-3- [2- (2-oxo-3-propionylamino-2.ϊ- pyridin-1-yl) -butyrylamino] -pentanoic acid
Figure imgf000066_0002
[0128] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; pink solid; IR (solid) 1644, 1585, 1518,
1214 cm-1; NMR (400 MHz, d6-DMSO) δ 0.8-0.9 (3H, m) , 1.05 (3H, t) , 1.9-2.1 (2H, m) , 2.4-2.5 (2H, m) , 2.6-2.95 (2H, ) , 4.2-4.5(2H, m) , 5.1-5.5 (3H, m) , 6.3-6.35 (IH, m) , 7.4-7.45 (IH, m) , 8.2-8.25 (IH, m) , 8.8-8.9 (IH, m)*, 9.1-9.15 (IH, m) ; 19F NMR (376 MHz,d6-DMSO, proton- decoupled) δ -226.7, -232.6; M+H 384.3, M-H 382.3. Example 30
(S) -3- [2- (3-Benzoylamino-2-oxo-2H-pyridin-l-yl) butyrylamino] -5-fluoro-4-oxo-pentanoic acid
Figure imgf000067_0001
[0129] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) - carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; pink solid; IR (solid) 1643,' 1522, 1204 cm-1; NMR (400 MHz, d6-DMSO) δ 0.75-0.85 (3H, m) , 1.9- 2.2 (2H, m) , 2.6-2.9 (2H, m) , 4.3-4.7(2H, m) , 5.1-5.6
(2H, m6.4-6.5 (IH, m) , 7.5-7.85 (4H, m) , 7.9-8.0 (IH, m) , 8.3-8.4 (IH, m) , 8.85-8.95 (IH, m) , 9.35 (IH, s) ; M+H 432.3, M-H 430.3.
Example 31 (S)-3-{2-[3-(2, 6-Dichloro-benzoylamino) -2-oxo-2H-pyridin- 1-yl] -butyrylamino} -5-fluoro-4-oxo-pentanoic acid
Figure imgf000067_0002
2-dihydro-pyridin-3-yl) - carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; white solid; IR (solid) 1682, 1645, 1580, 1516, 1216 cm-1; NMR (400 MHz, dδ-DMSO) δ 0.8-0.9 (3H, m) , 1.9-2.1 (2H, m) , 2.6-2.85 (2H, m) , 4.4-4.7(2H, m) , 5.1-5.5 (2H, m) , 6.4-6.5 (IH, m) , 7.5-7.6 (4H, m) , 8.33- 8.38 (IH, m) , 8.85-8.95 (IH, m) , 9.15-9.25 (IH, s) ; M+H 500.3, M-H 498.3. Example 32
( S ) -5-Fluoro-4-oxo-3- ( 2 - {2 -oxo-3 - [ (pyridine-2 -carbonyl) amino] -2if-pyridin-l-yl } -butyrylamino) -pentanoic acid
Figure imgf000068_0001
[0131] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) - carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; cream solid; IR (solid) 1685, 1644, 1521 cm- 1; NMR (400 MHz, d6-DMSO) δ 0.81-0.86 (3H, m) , 1.90- 2.05 (IH, m) , 2.06-2.19 (IH, m) , 2.54-2.90 (2H, m) , 4.58- 4.72 (IH, m) , 5.07-5.31 (2H, m) , 5.42-5.57 (IH, m) , 6.40- 6.44 (IH, m) , 7.47-7.49 (IH, m) , 6.68-7.72 (IH, m) , 8.09- 8.11 (IH, m) , 8.18 (IH, d) , 8.45-8.47 (IH, m) , 8.73-8.75 (IH, m) , 8.87 (IH, dd) , 10.74 (IH, s) , 12.45 (IH, brd s); 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -226.8,
-230.4, -230.6, -231.0, -232.5, -232.6, -232.8, -232.9; M+H 433.4, M-H 431.4.
Example 33 (S) -5-Fluoro-4-oxo-3- [2- (2-oxo-3-phenylacetylamino-2H- pyridin-1-yl) -butyrylamino] -pentanoic acid
Figure imgf000068_0002
[0132] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yi; carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; pink solid; IR (solid) 1644, 1672, 1742,
1785 cm-1; IH NMR (400 MHz, d6-DMSO) δ 0.7-0.8 (3H, m) , 1.8-2.2 (2H, m) , 2.5-3.2 (2H, m) , 3.8 (2H, s) , 4.2-4.7 (2H, m) , 5.1-5.5 (2H, m) , 6.3 (IH, m) , 7.2-7.4 (6H, m) , 8.2 (IH, m) , 8.5-9.4 (2H, m) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -226.7, -226.7, -230.4, -231.2, -232.6, -232.6; M+H 446.3, M-H 444.3.
Example 34 (S) -5-Fluoro-4-oxo-3- {2- [2-oxo-3- (2 -m-tolyl -acetyl amino) 2iϊ-pyridin-l-yl] -butyrylamino} -pentanoic acid
Figure imgf000069_0001
[0133] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) - carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; ochre solid; IR (solid) 1644, 1678 cm-1; 1H NMR (400 MHz, d6-DMSO) δ 0.7-0.8(3H, m) , 1.8-2.2 (2H, m) , 2.3 (3H, s), 2.5-3.2 (2H, m) , 3.7-3.8 (2H, s) , 4.2-5.5 (4H, m) , 6.3 (IH, m) , 7.0-7.3 (4H, m) , 7.4 (IH, m) , 8.2 (IH, m) , 8.5-8.9 (IH, m) , 9.2-9.3 (IH, m) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -226.7, -226.7, -230.4, -231.2, -232.6, -232.7; M+H 460.3, M-H 459.4.
Example 35 (S) -5-Fluoro-4-oxo-3- [2- (2-oxo-3-propionylamino-2H- pyridin-1-yl) -pentanoylamino] -pentanoic acid
Figure imgf000069_0002
[0134] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; white solid; NMR (400 MHz, d6-DMSO) δ 0 0.85-0.95 (3H, m) , 1.0-1.1 (3H, m) , 1.1-1.17 (2H, m) , 1.9-2.0 (2H, m) , 2.4-2.5 (2H, m) , 2.6-2.90 (2H, m) , 4.5- 4.65 (IH, m) , 5.1-5.5 (3H, m) , 6.3-6.35 (IH, m) , 7.4-7.43
(IH, m) , 8.2-8.23 (IH, m) , 8.8-8.9 (IH, m) , 9.05-9.1 (IH, m) ; 19F NMR (376 MHz,d6-DMSO, proton-decoupled) δ -226.7, -232.6; M+H 398.4, M-H 396.4.
Example 36
(S) -5-Fluoro-3- [4-methyl-2- (2-oxo-3-propionylamino-2H- pyridin-1-yl) -pentanoylamino] -4-oxo-pentanoic acid
Figure imgf000070_0001
[0135] Prepared from (2-oxo-l, 2-dihydro-pyridin-3-yl) - carbamic acid benzyl ester and 3-Amino-5-fluoro-4- hydroxy-pentanoic acid tert-butyl ester according to methods A-G; pink solid; 1H NMR (400 MHz, d6-DMSO) δ 0.'85(6H, m) , 1.05 (3H, t) , 1.30 (IH, m) , 1.70-2.10 (2H, 2 x m) , 2.30-3.00 (4H, m) , 4.60-4.80 (IH, m) , 5.05-5.40 (2H, m) , 5.65 (IH, m) , 6.35 (IH, m) , 7.45 (IH, m) , 8.25 (IH, m) , 8.95 (IH, m) , 9.15 (IH, m) ; 19F NMR. (376 MHz, d6- DMSO, proton-decoupled) δ -226.7, -232.5; M+H 412.3. Example 37
(S) -5-Fluoro-3- [2- (5-methyl-2-oxo-3-phenylacetylamino-2-:-"- pyridin-1-yl) -butyrylamino] -4-oxo-pentanoic acid
Figure imgf000070_0002
[0136] Prepared from (5-Methyl-2-oxo-l, 2-dihydro- pyridin-3-yl) -carbamic acid benzyl ester and 3-Amino-5- fluoro-4-hydroxy-pentanoic acid tert-butyl ester according to methods A-G; yellow solid; IR (solid) 1654, 1741, 1785 cm-1; 1H NMR (400 MHz, d6-DMSO) δ 0.7-0.8 (3H, m) , 1.8-2.2 (5H, m) , 2.5-3.2 (2H, m) , 3.8 (2H, s) , 4.2- 5.5 (4H, m) , 7.1-7.4 (6H, m) , 8.1(1H, m) , 8.4-8.9 (IH, m)", 9.2-9.4 (IH, m) ; 19F NMR (376 MHz, d6-DMSO, proton- decoupled) δ -226.7, -226.7, -227.5, -230.5, -231.3, -232.6, -232.6, -233.4; M+H 460.4, M-H 458.4.
Example 38 (S, S) -4-0x0-3- {2- [2-oxo-3- (thiazol-2-ylamino) -2Jϊ-pyridin- 1-yl] -butyrylamino} -5- (2,3,5, 6-tetrafluoro-phenoxy) - pentanoic acid
Figure imgf000071_0001
Method I :
3- (Thiazol-2-ylamino) -lH-pyridin-2-one
Figure imgf000071_0002
[0137] To a solution of 3-Amino-lJ-"-pyridin-2-one (2.0 g, 18.7 mmol) in water (2 mL) was added 15% HCl (10 mL,
18 mmol) followed by ammonium thiocyanate (1.5 g, 18 mmol) and the mixture was heated to reflux for two hours. Upon cooling the intermediate thiourea was found to precipitate as a red-brown solid. The mixture was filtered and the solid washed with water (5 L) . To a solution of the thiourea (1.3 g, 7.7 mmol) in EtOH (20 mL) and water (5 mL) was added chloroacetaldehyde (2.3 mL) , 16.4 mmol) and the mixture was heated to reflux for four hours. On cooling, the mixture was diluted with EtOAc (30 mL) and washed with 10% NaHC03 and brine. The organic phase was dried over MgS04 and concentrated in vacuo . The residue was purified by flash column chromatography (100% EtOAc) to afford the title compound as a pale green solid (1.43 g, 40%): 1H NMR (400 MHz, CDC13) δ 1.6 (IH, s), 6.45 (IH, t) , 6.75 (IH, s) , 7.05- 7.10 (IH, m) , 7.40-7.42 (IH, m) , 8.35-8.5 (2H, m) ; M+H 194.1, M-H 192.1.
[0138] This intermediate was involved in the sequence described in methods A and B-G to afford the example 38 as a white solid; IR (solid,) 1648, 1593, 1517, 1490 cm-1; NMR (400 MHz, d6-DMSO) δ 0.75-0.85 (3H, t) , 1.9-2.2 (2H, m) , 2.6-2.8 (2H, m) , 4.6-4.7 (IH, m) , 5.2-5.3 (2H, m) , 5.35-5.45 (IH, m) , 6.3-6.35 (IH, m) , 6.96-6.98 (IH, m) , 7.2-7.3 (2H, m) , 7.5-7.65 (IH, m) , 8.4-8.43 (IH, m) , 8.8-8.9(lH, 2 x d) , 9.9 (IH, br s) , 12.5 (IH, brd s) ; 19F NMR (376 MHz, d6-DMSO, proton-decoupled) δ -141.0, -156.9; M+H 557.2, M-H 555.2.
Example 39 (S, S) -4-0x0-3- [2- (2-oxo-3-propylamino-2H-pyridin-1-yl) - butyrylamino] -5- (2,3,5, 6-tetrafluoro-phenoxy) -pentanoic acid
Figure imgf000072_0001
Method J:
(S) -2- [3- (Benzyloxycarbonyl-propyl-amino) -2-oxo-2H- pyridin-1-yl] -butyric acid tert-butyl ester
Figure imgf000072_0002
[0139] To a solution of (S)-2-(3-
Benzyloxycarbonylamino-2-oxo-2H-pyridin-l-yl) -butyric acid tert-butyl ester (100 mg, 0.26 mmol) in anhydrous DMF (3 mL) was added NaH (60% dispersion, 10 mg, 0.26 mmol) and the reaction was stirred at ambient temperature for 30 minutes. Propyliodide (30 μL, 0.31 mmol) was added dropwise and the reaction stirred at ambient temperature overnight . The mixture was concentrated in vacuo to a solid and partitioned between EtOAc (10 mL) and, water (10 mL) . The organic layer was separated, dried over MgS04, and concentrated in vacuo . The residue was purified by flash column chromatography (30% EtOAc/ hexane) to afford the title compound as a pale green solid (1.43g, 40%): NMR (400 MHz, CDCl3) δ 0.85-0.95 (6H, m) , 1.35 (9H, s) , 1.55-1.65 (2H, m) , 1.85-1.95 (IH, m) , 2.20-2.27 (IH, m) , 3.6-3.7 (2H, m) , 5.15-5.2 (2H, m) , 5.5-5.6 (IH, m) , 6.25 (IH, t) , 7.25-7.45 (7H, m) ; M+H 429.4. [0140] This intermediate was involved in the sequence described in methods C-G and finally subjected to hydrogenolysis as described in method B to afford example 39 as an off-white solid; IR (solid) 1581, 1517, 1489, 938 cm-1; NMR (400 MHz, dδ-DMSO) δ 0.80 (3H, t) , 0.9 (3H, t), 1.5-1.6 (2H, m) , 1.8-2.05 (2H, m) , 2.5-2.7 (2H, m) , 2.9-3.0 (2H, m) , 4.6-4.7 (IH, m) , 5.1-5.4 (3H, m) , 6.1-6.2 (2H, m) , 6.85-6.9 (IH, m) , 7.5-7.65 (IH, m) , 8.7-8.90 (IH, 3 x d) , 12.5 (IH, brd s) ; M+H 516.2, M-H 514.2.
Example 40 Enzyme Assays
[0141] The assays for caspase inhibition are based on the cleavage of a fluorogenic substrate by recombinant, purified human Caspases -1, -3, or -8. The assays are run in essentially the same way as those reported by Garcia-Calvo et al. (J". Biol . Chem. 273 (1998), 32608- 32613), using a substrate specific for each enzyme. The substrate for Caspase-1 is Acetyl-Tyr-Val-Ala-Asp-amino- 4-methylcoumarin. The substrate for Caspases -3 and -8 is Acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin. Both substrates are known in the art. [0142] The observed rate of enzyme inactivation at a particular inhibitor concentration, k0bS, is computed by direct fits of the data to the equation derived by Thornberry et al. (Biochemistry 33 (1994), 3943-3939) using a nonlinear least-squares analysis computer program (PRISM 2.0; GraphPad software). To obtain the second order rate constant, kinact, k0bS values are plotted against their respective inhibitor concentrations and kιnact values are subsequently calculated by computerized linear regression. [0143] Inhibition of caspases-1, -3, and -8 activity for selected compounds of this invention was determined by the above method. Compounds 1-39 inhibited caspase-1 with a inact of >200,000 (M^s-1) , caspase-3 with a kinact" of at >50,000 (kinac (M^s"1) , and caspase-8 with a kinact of at >50,000 (kinact (M'V1) .
Example 41 Inhibition of IL-lβ secretion from Whole Blood
[0144] Human blood is freshly drawn from healthy donors and diluted 1:2 in PBS. To 500 μl of diluted blood 50ml of prediluted test compound in RPMI medium and 10 ml LPS (5ng/ml final concentration on the plate) are added (LPS, Serotype 0111:B4, Sigma L3012). After stimulation for 18 hours supernatants are collected and assayed for IL-lβ levels using the appropriate ELISA kit
(R&D systems) .
[0145] Table 2 below shows inhibition of IL-lβ secretion from human whole blood for selected compounds of this invention as determined individually by the above methods . Table 2. Inhibition of IL-lβ secretion
Figure imgf000075_0001
Example 42 Hypoxia-induced apoptosis of rat cortical neurons
[0146] Cortical neurons are dissociated from Wistar rat embryos (E17) by a modification of the procedure of Rogers et al. 1997, Brain Res . Bulletin, 44:131. Briefly, cerebral cortices are isolated aseptically from 15-20 Wistar rat embryos. A cell suspension is prepared by mincing the cerebral cortices and digesting them with papain. Cells are washed with ovomucoid enzyme inhibitor and DNasel and plated onto Poly-D lysine coated plates in high glucose DMEM containing 10% heat-inactivated fetal calf serum, L-glutamine, penicillin and streptomycin.
The yield of neurons is 10x7 per embryo and they are 80-
90% viable as assessed by Trypan blue exclusion.
[0147] The neurons are cultured in complete medium at
37 °C in a normal atmosphere for 48 hours prior to the hypoxia experiments. For hypoxia, the normal cell medium is replaced by oxygen-depleted serum-free medium. Cells are incubated in an atmosphere of 95% N2/5% C02 for various lengths of time. Compounds are dissolved in DMSO at lOOmM then diluted in medium and added to the culture from time=0. The level of apoptosis is measured using a Cell Death Detection ELISA kit (Roche) which detects DNA fragmentation. Plates are read at 405nm. Controls included cells cultured in aerobic conditions in serum- containing medium (+serum) and cells cultured in aerobic conditions in serum-deprived medium (-serum) . [0148] Table 3 shows the results of the activity of selected compounds of this invention tested individually in the Hypoxia-induced apoptosis of rat cortical neurons.
Figure imgf000076_0001
Example 43 Anti-Fas Induced Apoptosis Assay
[0149] Cellular apoptosis may be induced by the binding of Fas ligand (FasL) to its receptor, CD95 (Fas) . CD95 is one of a family of related receptors, known as death receptors, which can trigger apoptosis in cells via activation of the caspase enzyme cascade. The process is initiated by the binding of the adapter molecule FADD/MORT-1 to the cytoplasmic domain of the CD-95 receptor-ligand complex. Caspase-8 then binds FADD and becomes activated, initiating a cascade of events that involve the activation of downstream caspases and subsequent cellular apoptosis. Apoptosis can also be induced in cells expressing CD95 e.g., the Jurkat E6.1 T cell lymphoma cell line, using an antibody, rather than FasL, to crosslink the cell surface CD95. Anti-Fas- induced apoptosis is also triggered via the activation of caspase-8. This provides the basis of a cell based assay to screen compounds for inhibition of the caspase-8- mediated apoptotic pathway. Experimental Procedure
[0150] Jurkat E6.1 cells are cultured in complete medium consisting of RPMI-1640 (Sigma No) + 10% foetal calf serum (Gibco BRL No.10099-141) + 2mM L-glutamine (Sigma No. G-7513). The cells are harvested in log phase of growth. 100 ml of cells at 5-8x105 cells/ml are transferred to sterile 50ml Falcon centrifuge tubes and centrifuged for 5 minutes at lOOxg at room temperature. The supernatant is removed and the combined cell pellets resuspended in 25ml of complete medium. The cells are counted and the density adjusted to 2xl06cells/ml with complete medium.
[0151] The test compound is dissolved in dimethyl sulfoxide (DMSO) (Sigma No. D-2650) to give a lOOmM stock solution. This is diluted to 400μM in complete medium, then serially diluted in a 96-well plate prior to addition to the cell assay plate.
[0152] lOOμl of the cell suspension (2x106 cells) is added to each well of a sterile 96-well round-bottomed cluster plate (Costar No. 3790) . 50μl of compound solution at the appropriate dilution and 50μl of anti-Fas antibody, clone CH-11 (Upstate, Cat No.l 544 675) at a final concentration of lOng/ml, are added to the wells. Control wells are set up minus antibody and minus compound but with a serial dilution of DMSO as vehicle control. The plates are incubated for 16-18hrs at 37°C in 5% C02 and 95% humidity. [0153] Apoptosis of the cells is measured by the quantitation of DNA fragmentation using a 'Cell Death Detection Assay' from Roche diagnostics, No. 1544 675. After incubation for 16-18hrs the assay plates are centrifuged at lOOxg at room temperature for 5 minutes. 150μl of the supernatant are removed and replaced by 150μl of fresh complete medium. The cells are then harvested and 200μl of the lysis buffer supplied in the assay kit are added to each well. The cells are triturated to ensure complete lysis and incubated for 30 minutes at 4°C. The plates are then centrifuged at 1900xg for 10 minutes and the supernatants diluted 1:20 in the incubation buffer provided. lOOμl of this solution is then assayed according to the manufacturer's instructions supplied with the kit. OD405nm is measured 20 minutes after addition of the final substrate in a SPECTRAmax Plus plate reader (Molecular Devices) . OD405nm is plotted versus compound concentration and the IC50 values for the compounds are calculated using the curve-fitting program SOFTmax Pro (Molecular Devices) using the four parameter fit option.
Selected compounds have been tested in this assay and shown to inhibit Fas-induced apoptosis of Jurkat cells with IC50 values between O.OOlμM and 0.15μM. Table 4. Activity in FAS-induced Apoptosis Assay
Figure imgf000078_0001
[0154] While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments which utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example above.

Claims

We claim:
A compound of formula I :
Figure imgf000080_0001
wherein:
R1 is R6C(0)-, HC(0) RbS02-, Rb0C(0) (R6)2NC(0)
(R5) (H)NC(O) R6C(0)C(0) R6-, (R6)2NC(0)C(0)
(R6) (H)NC(0)C(0)-, or R6OC (0) C (0) -; R2 is hydrogen, -CF3, -halo, -OR7, -N02, -0CF3, -CN, or R8; R3 is hydrogen or (C1-C4) -aliphatic-; R4 is -COOH or -COOR8;
R5 is -CH2F or -CH20-2 , 3 , 5 , 6-tetrafluorophenyl; R6 is (C1-C12) -aliphatic- (C3-CIO) -cycloaliphatic-, (C6- CIO) -aryl-, (C3-CIO) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10)- heteroaryl (C1-C12) -aliphatic-, or two Rs groups bound to the same atom form together with that atom a 3- to 10-membered aromatic or nonaromatic ring; wherein any ring is optionally fused to a (C6-C10) aryl, (C5- C10) heteroaryl, (C3-C10) cycloalkyl, or a (C3- C10) heterocyclyl; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R) , S, SO, and S02; and wherein R6 is substituted with up to 6 substituents independently selected from R;
R is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, =NR7, =N(OR7) , 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7,. -S02R7, -S02N(R7)2, -SO3R7, -C(0)R7, -C(0)C(0)R7, -C(0)C(0)OR7, -C (0) C (O)N(R7) 2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)OR7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC(0)N(R7)2, -C(S)N(R7)2, - (CH2) 0-2NHC (0) R7, -N(R7)N(R7)COR7, -N(R7)N(R7)C(0)OR7, -N (R7) N(R7) CON (R7) 2 , -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7) C (0) OR7, -N(R7) C (O)R7, -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S)N(R7) 2, -N(COR7)COR7, -N(OR7)R7, -C (=NH) N (R7) 2 , -C (0) N(OR7) R7 , -C(=NOR7)R7, -OP(O) (OR7)2, -P(0)(R7)2, -P(0)(OR7)2, or -P(O) (H) (OR7); two R7 groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or nonaromatic ring having up to 3 heteroatoms independently selected from N, N(R) , 0, S, SO, or S02, wherein the ring is optionally fused to a (C6-C10) aryl, (C5- C10) heteroaryl, (C3-CIO) cycloalkyl, or a (C3- C10) heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J2; or each R7 is independently selected from: hydrogen- ,
(C1-C12 -aliphatic-, (C3-C10 -cycloaliphatic- , (C3-C10 -cycloaliphatic- (C1-C12) -aliphatic-, (C6-C10 -aryl-, (C6-C10 -aryl- (C1-C12) aliphatic-, (C3-C10 -heterocyclyl- , (C6-C10 -heterocyclyl- (C1-C12) aliphatic-, (C5-C10 -heteroaryl-, or (C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein R7 has up to 3 substituents selected independently from J2; and
J2 is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, =N(R7) , =NO(R7), 1, 2-methylenedioxy, " 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C (0) C (0) OR7, -C(0)C(0)N(R7)2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)OR7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, , -C(S)N(R7)2, -(CH2)0-2NHC(O)R7, -N(R7)N(R7) COR7,
-N(R7)N(R7)C(0)OR7, -N(R7)N(R7)CON(R7)2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7)C(0)OR7, - (R7) C (O) R7 , -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S)N(R7) 2, -N(COR7)COR7, -N(OR7)R7, -CN, -C (=NH) N (R7) 2 , -C(0)N(OR7)R7, -C(=NOR7)R7, -OP (O) (OR7) 2, -P(0)(R7)2, -P(O) (OR7)2, or -P(O) (H) (OR7) ; and R8 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, or (C5-C10)- heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N, N(R) , S, SO, and S02; and wherein R8 is optionally substituted with up to 6 substituents independently selected from R.
2. A compound of formula I :
Figure imgf000083_0001
wherein:
R1 is R6C(0)-, R6S02-, R6OC(0)-, (R6)2NC(0)-, R6C(0)C(0)
R° (R6)2NC(0)C(0)-, or R6OC(0)C(0)
R2 is hydrogen, -CF3, -halo, -OR7, -N02, -OCF3, -CN, or R8; R3 is hydrogen or (C1-C4) -aliphatic-; R4 is -COOH or -COOR8; R5 is -CH2F or -CH20-2 , 3 , 5 , 6-tetrafluorophenyl;
R6 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- CIO) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10)- heteroaryl (C1-C12) -aliphatic-, or two Rδ groups bound to the same atom form together with that atom a 3- to 10-membered aromatic or nonaromatic ring; wherein any ring is optionally fused to a (C6-C10) aryl, (C5- CIO) heteroaryl, (C3-CIO) cycloalkyl, or a (C3-
C10) heterocyclyl; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R), S, SO, and S02; and wherein R6 is substituted with up to 6 substituents independently selected from R;
R is halogen, -OR7, -OC (0)N(R7)2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, 1, 2-methylenedioxy, 1,2- ethy1enedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -SO3R7, -C(0)R7, -C(0)C(0)R7, -C(0)CH2C(0)R7, -C(S)R7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, -C(S)N(R7)2, -(CH2)0-2NHC(O)R7, -N(R7)N(R7)COR7, -N(R7)N(R7) C (0) OR7, -N(R7)N(R7)CON(R7)2, -N(R7)S02R7, -N(R7) S02N(R7) 2, -N(R7)C(0)OR7, -N(R7)C(0)R7, -N(R7) C (S)R7, -N(R7) C (0) N(R7) 2 , -N(R7)C(S)N(R7)2, -N(COR7)COR7, -N(OR7)R7, -C (=NH)N(R7) 2, -C(0)N(OR7)R7, -C(=NOR7)R7, -OP (O) (OR7) 2, -P(0)(R7)2, -P(O) (OR7)2, or -P(O) (H) (OR7) ; two R7 groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or non- , aromatic ring having up to 3 heteroatoms independently selected from N, N(R) , 0, S, SO, or S02, wherein the ring is optionally fused to a (C6-C10) aryl, (C5- C10) heteroaryl, (C3-CIO) cycloalkyl, or a (C3- CIO) heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J2; or each R7 is independently selected from: hydrogen- ,
(C1-C12) -aliphatic-, (C3-C10) -cycloaliphatic-,
(C3-C10) -cycloaliphatic- (C1-C12) -aliphatic-, (C6-C10)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-C10) -heterocyclyl-, (C6-C10) -heterocyclyl- (C1-C12) aliphatic-,
(C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein R7 has up to 3 substituents selected independently from J ; and J2 is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -0CF3, -R7, oxo, thioxo, 1, 2-methylenedioxy, 1,2- ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -SO3R7, -C(0)R7, -C(0)C(0)R7, -C(0)CH2C(0)R7, -C(S)R7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, -C(S)N(R7)2, -(CH2)0-2NHC(O)R7, -N(R7)N(R7) COR7, -N(R7)N(R7)C(0)OR7, -N(R7)N(R7)CON(R7)2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7)C(0)OR7, -N(R7) C (0) R7,
-N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S)N(R7) 2, -N(COR7)COR7, -N(OR7)R7, -CN, -C (=NH) N(R7) 2 , -C(0)N(OR7)R7, -C(=N0R7)R7, -OP (0) (OR7) 2, -P(0)(R7)2, -P(O) (OR7)2, or -P(O) (H) (OR7) ; and R8 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, or (C5-C10)- heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N, N(R) , S, SO, and S02.
3. The compound according to claim 1 or claim 2, wherein R5 is -CH20-2, 3 , 5, 6-tetrafluorophenyl .
4. The compound according to claim 1 or claim 2, wherein R5 is -CH2F.
5. The compound according to any one of claims
1-4, wherein R1 is R6C(0)-.
6. The compound according to any one of claims 1-4, wherein R1 is R6S02-.
7. The compound according to any one of claims 1-4, wherein R1 is R6-.
8. The compound according to any one of claims 1-4, wherein R1 is (R6)2NC(0)-.
9. The compound according to any one of claims
1-4, wherein R1 is (R6) (H)NC (0) - .
10. The compound according to any one of claims 1-4, wherein R1 is (R6)0C(0)-.
11. The compound according to any one of claims 1-10, wherein R6 is (C1-C4) -aliphatic-, (C3-C10)- cycloaliphatic, (C3-CIO) -heterocyclyl, (C5-C10)- heteroaryl, (C6-C10) -aryl-, or (C6-C10) -aryl- (C1-C12) -; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R) , S, SO, and S02; and wherein R6 is optionally substituted.
12. The compound according to any one of claims 1-10, wherein R6 is (C1-C4) -aliphatic-, (C5-C10)- heteroaryl-, or (C6-C10) -aryl-, wherein the heteroaryl or aryl is optionally substituted or wherein each R6 together with the N-atom is a (C3-C7) -cycloaliphatic group.
13. The compound according to any one of claims 1-10, wherein Rs is (C1-C4) -aliphatic- or (C6-C10)- aryl-, wherein the aryl is optionally substituted or wherein each R6 together with the N-atom is a (C3-C7)- cycloaliphatic group.
14. The compound according to any one of claims 1-13, wherein the aliphatic is (C1-C4) -alkyl- , 56 -
15. The compound according to any one of claims 1-14, wherein R2 is hydrogen, CF3, or CH3.
16. The compound according to any one of claims 1-15, wherein R2 is hydrogen or CF3.
17. The compound according to any one of claims 1-16, wherein R3 is (C1-C4) -alkyl- .
18. The compound according to any one of claims 1-17, wherein R3 is ethyl.
19. A compound selected from Table 1.
20. A pharmaceutical composition comprising: a) a compound according to any one of claims 1-19; and b) a pharmaceutically acceptable carrier, adjuvant or vehicle.
21. A method for treating IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, a viral mediated disease, or liver disease in a patient comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1-19 or a pharmaceutical composition according to claim 20.
22. A method for treating rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus , scleroderma, chronic thyroiditis, Grave's disease, myasthenia gravis, autoimmune neutropenia, autoimmune hemolytic anemia, thrombocytopenia, juvenile rheumatoid arthritis, gout, Behcet's syndrome, Still's syndrome, macrophage activation syndrome, sarcoidosis, Muckle-Wells syndrome, familial cold urticaria, chronic infantile neurological cutaneous and articular syndrome, familial mediterranean fever, TNFRl-Associated Periodic Syndrome (TRAPS) , Hyper-IgD periodic fever Syndrome (HIDS), Blau's syndrome, psoriasis, atopic dermatitis, scarring, alopecia, acne vulgaris, pemphigus, asthma, adult respiratory distress syndrome, cystic fibrosis, emphysema, chronic bronchitis, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, inflammatory peritonitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, autoimmune gastritis, H.pylori-associated gastric and duodenal ulcer disease, diabetes, pancreatitis, glomerulonephritis, chronic active hepatitis, excess dietary alcohol intake disease, renal disease, polycystic kidney disease, burns, organ apoptosis after burn injury, haemorrhagic shock, organ failure, endometriosis, graft vs. host disease, organ transplant rejection, leukemia, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, chronic heart disease, acute heart disease, myocardial infarction, myocardial ischemia, congestive heart failure, atherosclerosis, coronary artery bypass graft (CABG) , a complication associated with a coronary artery bypass graft, acute coronary syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, traumatic brain injury, spinal cord injury, neurological damage due to stroke, diabetic neuropathy, acute and chronic pain, uveitis, retinal disorders, diabetic retinopathy, glaucoma, keratitis, viral mediated disease, sepsis, septic shock, shigellosis, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, Japanese encephalitis, HIV infection, tuberculosis, meningitis, Pseudomonas infection, Acinetobacter infection, or aging in a patient comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1-19 or a pharmaceutical composition according to claim 20.
23. The method according to claim 22, wherein the disease is osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus , scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, insulin-dependent diabetes mellitus (Type I) , autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, graft vs. host disease, osteoporosis, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, sepsis, septic shock, Shigellosis, cerebral ischemia, myocardial 59-
ischemia, spinal muscular atrophy, or neurological damage due to stroke.
24. The method according to claim 22, wherein said disease is a complication associated with a coronary artery bypass graft .
25. A method for inhibiting a caspase-mediated function in a patient comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1-19 or a pharmaceutical composition according to claim 20.
26. The method for decreasing IGIF or IFN-γ production in a patient comprising administering a pharmaceutically effective amount of a compound according to any one of claims 1-19 or a pharmaceutical composition according to claim 20.
27. A method of preserving cells, said method comprising the step of bathing the cells in a solution of the compound according to any one of claims 1-19.
28. The method according to claim 27, wherein said cells are in: a) an organ intended for transplant; or b) a blood product.
29. A method of treating cancer using immunotherapy, wherein said immunotherapy comprises as a component thereof a compound according to any one of claims 1-19. -go-
so. The method according to any one of claims 20-29 wherein the method comprises administering an additional therapeutic agent.
31. A process for preparing a compound of formula (I) :
Figure imgf000091_0001
(I) R1 is R6C(0)-, HC(O)-, R6S02-, R6OC(0)-, (R6)2NC(0)-, (R6) (H)NC(O)-, R6C(0)C(0)-, R6-, (R6) 2NC (0) C (0) -, (R6) (H)NC(0)C(0)-, or R60C (0) C (0) - ; R2 is hydrogen, -CF3, -halo, -OR7, -N02, -0CF3, -CN, or R8; R3 is hydrogen or (C1-C4) -aliphatic-; R4 is -C00H or -COOR8; R5 is -CH2F or -CH20-2 , 3 , 5, 6-tetrafluorophenyl;
R6 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- CIO) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10)- heteroaryl (C1-C12) -aliphatic-, or two R6 groups bound to the same atom form together with that atom a 3- to 10-membered aromatic or nonaromatic ring; wherein any ring is optionally fused to a (C6-C10) aryl, (C5- CIO) heteroaryl, (C3-CIO) cycloalkyl, or a (C3-
C10) heterocyclyl; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R), S, SO, and S02; and wherein R6 is substituted with up to 6 substituents independently selected from R; R is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, =NR7, =N(OR7), 1, 2 -methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7,
-S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C (0) C (0) OR7, -C(0)C(0)N(R7)2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)OR7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, -C(S)N(R7)2, -(CH2)0-2NHC(O)R7, -N(R7)N(R7) COR7, -N(R7)N(R7)C(0)OR7, -N(R7)N(R7) CON(R7) 2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7)C(0)OR7, -N(R7) C (O)R7, -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S) N (R7) 2, -N(COR7)COR7, -N(OR7)R7, -C (=NH) N(R7) 2, -C (O) N(OR7) R7, -C(=NOR7)R7, -OP(O) (OR7)2, -P(0) (R7)2, -P(0) (OR7)2, or -P(O) (H) (OR7) ; two R7 groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or nonaromatic ring having up to 3 heteroatoms independently selected from N, N(R) , O, S, SO, or S02, wherein the ring is optionally fused to a (C6-C10) aryl, (C5-
C10) heteroaryl, (C3 -CIO) cycloalkyl, or a (C3- C10) heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J2; or each R7 is independently selected from: hydrogen- ,
(C1-C12 ) -aliphatic- , (C3-C10) -cycloaliphatic-,
(C3-C10) -cycloaliphatic- (C1-C12) -aliphatic-, (C6-C10)-aryl-, (C6-C10) -aryl- (C1-C12) aliphatic-,
(C3-C10) -heterocyclyl-, (C6-C10) -heterocyclyl- (C1-C12) aliphatic-, (C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein R7 has up to 3 substituents selected independently from J2; and J2 is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, =NR7, =N(OR7), 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C (0) C (0) OR7, -C(0)C(0)N(R7)2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)0R7, -C(0)0R7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, -C(S)N(R7)2, -(CH2)o-2NHC(0)R7, -N(R7) N(R7) COR7, -N(R7)N(R7)C(0)OR7, -N(R7)N(R7)CON(R7)2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7)C(0)OR7, -N(R7) C (0) R7 , -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S) N (R7) 2, -N(COR7)COR7, -N(OR7)R7, -CN, -C (=NH)N(R7) 2,
-C(0)N(OR7)R7, -C(=N0R7)R7, -OP (0) (OR7) 2, -P(0)(R7)2, -P(O) (OR7)2, or -P(O) (H) (OR7) ; and R8 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, or (C5-C10)- heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N, N(R) , S, SO, and S02; and wherein R8 is optionally substituted with up to 6 substituents independently selected from R; comprising: (a) reacting a compound of formula (III) :
Figure imgf000094_0001
(III) wherein:
R9 is -N02, -C(0)OR10, -CN, R6C(0)N(H)-, R6S02N(H)-, R6OC(0)N(H)-, (R6)2NC(0)N(H)-, R6C (0) C (O)N(H) -, R6N(H)-, (R6)2NC(0)C(0)N(H)-, or R6OC (0) C (O)N(H) -; R10 is independently hydrogen, (C1-C12) -aliphatic- (C3- C10) -cycloaliphatic-, (C6-C10) -aryl-, (C3-C10)- heterocyclyl-, (C5-C10) -heteroaryl-, (C3-C10)- cycloaliphatic- (C1-C12) -aliphatic-, (C6-C10) -aryl- (Cl- C12) -aliphatic-, (C3-C10) -heterocyclyl- (C1-C12) - aliphatic-, (C5-C10) -heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N(H) , N(R) , S, SO, and S02; and wherein R10 is optionally substituted with up to 6 substituents independently selected from R; and R, R2, R3 and R6 are as defined above;
with a compound of formula (IV)
Figure imgf000094_0002
(IV) wherein Y is either a carbonyl group or an OH group; and R4 and R5 are as defined above; in the presence of coupling conditions and a solvent;
provided that if Y is an OH group, then the process further comprises (b) oxidizing the OH group to provide the compound of formula (I) ; and
provided that if Ra is -N02, -C(0)OR , or -CN, the process comprises the further step of converting the -N02, -C(0)OR10, or -CN into R6C(0)N(H)-, R6S02N(H)-, R6OC(0)N(H) (R6)2NC(0)N(H)-, R6C(0)C(0)N(H)-, R6N(H)
(R6)2NC(0)C(0)N(H)-, or R6OC (0) C (O)N(H)
32. The process according to claim 31, wherein the compound of formula (III) :
Figure imgf000095_0001
(III) wherein
R2 is hydrogen, -CF3, -halo, -OR7, -N02, -OCF3, -CN, or R8;
R3 is hydrogen or (C1-C4) -aliphatic-;
R9 is -N02, -C(0)0R10, -CN, R6C(0)N(H)-, R6S02N(H)-,
R6OC(0)N(H)-, (R6)2NC(0)N(H)-, R6C (0) C (O)N(H) - , R6N(H)-,
(R6)2NC(0)C(0)N(H)-, or R6OC(0)C(0)N(H)-; R6 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6-
C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10) - heteroaryl (C1-C12) -aliphatic-, or two R6 groups bound to the same atom form together with that atom a 3- to 10-membered aromatic or nonaromatic ring; wherein any ring is optionally fused to a (C6-C10) aryl, (C5- C10) heteroaryl, (C3-CIO) cycloalkyl, or a (C3- CIO) heterocyclyl; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R) , S, SO, and S02; and wherein R6 is substituted with up to 6 substituents independently selected from R; R is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3,
-OCF3, -R7, oxo, thioxo, =NR7, =N(OR7), 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C (0) C (0) OR7, -C (0) C (O)N(R7) 2, -C(0)CH2C(0)R7, -C(S)R7, -C(θ')OR7, -OC(0)R7, -C(0)N(R7)2, -0C(O)N(R7)2, -C(S)N(R7)2, - (CH2) 0_2NHC (0) R7,
-N(R7)N(R7)COR7, -N(R7)N(R7)C(0)OR7, -N (R7) N(R7) CON (R7) 2 , -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7) C (0) OR7 , -N (R7) C (0) R7, -N(R7)C(S)R7, 7N(R7)C(0)N(R7)2, -N (R7) C (S) N (R7) 2, -N(COR7)COR7, -N(OR7)R7, -C (=NH) N(R7) 2 , -C (0) N (OR7) R7 , -C(=NOR7)R7, -0P(0) (OR7)2, -P(0)(R7)2, -P(0)(OR7)2, or -P(0) (H) (OR7); two R7 groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or nonaromatic ring having up to 3 heteroatoms independently selected from N, N(R) , 0, S, SO, or S02, wherein the ring is optionally fused to a (C6-C10) aryl, (C5- C10) heteroaryl, (C3-CIO) cycloalkyl, or a (C3- C10) heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J2; or each R7 is independently selected from: hydrogen- , (C1-C12) -aliphatic-, (C3-C10) -cycloaliphatic-,
(C3-C10) -cycloaliphatic- (C1-C12) -aliphatic-, (C6-C10)-aryl-,
(C6-C10) -aryl- (C1-C12) aliphatic-, (C3-CIO) -heterocyclyl-,
(C6-C10) -heterocyclyl- (C1-C12) aliphatic-, (C5-CIO) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein R7 has up to 3 substituents selected independently from J ; and
J2 is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, =NR7, =N(OR7), 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C (0) C (0) OR7, -C(0)C(0)N(R7)2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)0R7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, -C(S)N(R7)2, -(CH2)o-2NHC(0)R7, -N(R7)N(R7) COR7, -N(R7)N(R7)C(0)OR7, -N(R7)N(R7)CON(R7)2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7)C(0)OR7, -N(R7) C (O) R7, -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S)N(R7) 2, -N(COR7)COR7, -N(OR7)R7, -CN, -C (=NH) N (R7) 2, -C(0)N(OR7)R7, -C(=NOR7)R7, -OP (0) (OR7) 2, -P(0)(R7)2, -P(O) (OR7)2, or -P(O) (H) (OR7) ; and R8 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- CIO) -aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, or (C5-C10)- heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N, N(R) , S, SO, and S02; and wherein R8 is optionally substituted with up to 6 substituents independently selected from R;
is prepared by a process comprising: (c) reacting a compound of formula (V) :
Figure imgf000098_0001
(V) wherein: R10 is independently hydrogen, (C1-C12) -aliphatic- (C3- CIO) -cycloaliphatic-, (C6-C10) -aryl-, (C3-C10)- heterocyclyl-, (C5-C10) -heteroaryl-, (C3-C10)- cycloaliphatic- (C1-C12) -aliphatic-, (C6-C10) -aryl- (Cl- C12 ) -aliphatic- , (C3-C10) -heterocyclyl- (C1-C12 ) - aliphatic-, (C5-C10) -heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N, N(R) , S, SO, and S02; and
R, R2', R3, and R9 are as defined above ;
in a solvent in the presence of deprotecting conditions.
33. The process according to claim 32, wherein the compound of formula (V) :
Figure imgf000098_0002
(V) wherein R2, R3, R9, and R10 are as defined in claim 32;
is prepared by a process comprising: (d) reacting a compound of formula (VI)
Figure imgf000099_0001
(VI) wherein R2 and R9 are as defined in claim 32;
with a compound of formula (VII) :
Figure imgf000099_0002
(VII) wherein X is a suitable leaving group; and R3 and R10 are as defined above;
in the presence of a solvent and a base.
34. A process for preparing a compound of formula (VIII) :
Figure imgf000099_0003
(VIII) wherein: R2 is -CF3, -CI, -OR7, -N02, -OCF3, -CN, or R8;
R3 is hydrogen or (C1-C4) -aliphatic-;
R9 is -N02, -C(0)OR10, -CN, R6C(0)N(H)-, R6S02N(H)-,
R6OC(0)N(H)-, (R6)2NC(0)N(H)-, R6C (0) C (O)N(H) - , R6N(H)-, (R6)2NC(0)C(0)N(H)-, or R6OC (O) C (O)N(H) - ; R10 is independently hydrogen, (C1-C12) -aliphatic- (C3-
C10) -cycloaliphatic-, (C6-C10) -aryl-, (C3-C10)- heterocyclyl-, (C5-C10) -heteroaryl-, (C3-C10)- cycloaliphatic- (C1-C12) -aliphatic-, (C6-C10) -aryl- (Cl- C12) -aliphatic-, (C3-C10) -heterocyclyl- (C1-C12) - aliphatic-, (C5-C10) -heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N(H) , N(R) , S, SO, and S02; and wherein R10 is optionally substituted with up to 6 substituents independently selected from R;
R6 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- C10)-aryl-, (C3-CIO) -heterocyclyl-, (C5-C10)- heteroaryl- , (C3-C10) ,-cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- CIO) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10)- heteroaryl (C1-C12) -aliphatic-, or two R6 groups bound to the same atom form together with that atom a 3- to 10-membered aromatic or nonaromatic ring; wherein any ring is optionally fused to a (C6-C10) aryl, (C5- CIO) heteroaryl, (C3-CIO) cycloalkyl, or a (C3-
C10) heterocyclyl; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R) , S, SO, and S02; and wherein R6 is substituted with up to 6 substituents independently selected from R;
R is halogen, -OR7, -OC (0)N(R7)2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, =NR7, =N(0R7) , 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -SO3R7, -C(0)R7, -C(0)C(0)R7, -C(0)C(0)OR7, -C (0) C (O)N(R7 2/ -C(0)CH2C(0)R7, -C(S)R7, -C(S)OR7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC(0)N(R7)2, -C(S)N(R7)2, - (CH2) 0-2NHC (O)R7, -N(R7)N(R7)COR7, -N(R7)N(R7)C(0)OR7, -N(R7) N(R7) CON (R7) 2 , -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7) C (0) OR7, -N(R7) C (O) R7, -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N (R7) C (S) N (R7 2<
-N(COR7)COR7, -N(OR7)R7, -C ( =NH) N (R7 ) 2, -C (O)N(OR7) R7, -C(=NOR7)R7, -OP(O) (OR7)2, -P(0) (R7)2, -P(0) (OR7)2, or -P(O) (H) (OR7) ; two R7 groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or nonaromatic ring having up to 3 heteroatoms independently selected from N, N(R) , 0, S, SO, or S02, wherein the ring is optionally fused to a (C6-C10) aryl, (C5-
C10) heteroaryl, (C3-C10) cycloalkyl, or a (C3- C10) heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J2; or each R7 is independently selected from: hydrogen- ,
(C1-C12 ) -aliphatic- , (C3-C10) -cycloaliphatic-,
(C3-C10) -cycloaliphatic- (C1-C12) -aliphatic-, (Cδ-ClO)-aryl-, ' (C6-C10) -aryl- (C1-C12) aliphatic-,
(C3-C10) -heterocyclyl-,
(C6-C10) -heterocyclyl- (C1-C12) aliphatic-, (C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein R7 has up to 3 substituents selected independently from J2; and J2 is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, =NR7, =N(OR7) , 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C (0) C (O) OR7, ' -C(0)C(0)N(R7)2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)OR7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2 , -C(S)N(R7)2, -(CH2)0-2NHC(O)R7, -N(R7) N(R7) COR7, -N(R7)N(R7)C(0)OR7, -N(R7)N(R7)CON(R7)2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7)C(0)OR7, -N(R7) C (O) R7 , -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S)N(R7) 2„ -N(COR7)COR7, -N(OR7)R7, -CN, -C (=NH)N(R7) 2, -C(0)N(OR7)R7, -C(=NOR7)R7, -OP (O) (OR7) 2, -P(0)(R7)2, -P(O) (OR7) 2, or -P(O) (H) (OR7) ; and R8 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- CIO) -aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, or (C5-C10)- heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from O, N, N(R) , S, SO, and S02; and wherein R8 is optionally substituted with up to 6 substituents independently selected from R;
comprising the step of (e) reacting a compound of formula (IX) :
Figure imgf000102_0001
(IX) wherein R2 and R9 are as defined above;
with a compound of formula (VII) :
Figure imgf000103_0001
(VII) wherein R3 and R10 are as defined above; and X is a suitable leaving group;
in the presence of a solvent and a base.
35. A process for preparing a compound of formula (I)
Figure imgf000103_0002
(i) wherein:
R1 is R6C(0)-, R6S02-, R6OC(0)-, (R6)2NC(0)-, (R6) (H)NC (0) -,
R6C(0)C(0)-, R6-, (R6)2NC(0)C(0)-, (R6) (H)NC (0) C (0) - , or
R6OC(0)C(0)-;
R2 is hydrogen, -CF3, -halo, -OR7, -N02, -0CF3, -CN, or R8; R3 is hydrogen or (C1-C4) -aliphatic-;
R4 is -C00H or -C00R8;
R5 is -CH2F or -CH20-2 , 3 , 5 , 6-tetrafluorophenyl;
R5 is (C1-C12) -aliphatic- (C3-CIO) -cycloaliphatic-, (C6- C10)-aryl-, (C3-C10) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- CIO) -heterocyclyl- (C1-C12) -aliphatic-, (C5-C10) - heteroaryl (C1-C12) -aliphatic-, or two R6 groups bound to the same atom form together with that atom a 3- to 10-membered aromatic or nonaromatic ring; wherein any ring is optionally fused to a (C6-C10) aryl, (C5- C10) heteroaryl, (C3-CIO) cycloalkyl, or a (C3- C10)heterocyclyl; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, N(R) , S, SO, and S02; and wherein R6 is substituted , with up to 6 substituents independently selected from
R'- R is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -0CF3,
-R7, oxo, thioxo, =NR7, =N(0R7), 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C (0) C (0) OR7, -C(0)C(0)N(R7)2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)OR7, -C(0)OR7, -0C(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, -C(S)N(R7)2, -(CH2)0_2NHC(O)R7, -N(R7) N(R7) COR7, -N(R7)N(R7)C(0)OR7, -N(R7)N(R7)CON(R7)2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7)C(0)OR7, -N(R7) C (0) R7,
-N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S)N(R7) 2, -N(COR7)COR7, -N(OR7)R7, -C (=NH)N(R7) 2, -C (O)N(OR7) R7, -C(=NOR7)R7, -OP(0) (OR7)2, -P(0)(R7)2, -P(0)(OR7)2, or -P(O) (H) (OR7); two R7 groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or nonaromatic ring having up to 3 heteroatoms independently selected from N, N(R) , 0, S, SO, or S02, wherein the ring is optionally fused to a (C6-C10) aryl, (C5- CIO) heteroaryl, (C3-C10) cycloalkyl, or a (C3-
C10) heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J2; or each R7 is independently selected from: hydrogen- ,
(C1-C12 ) -aliphatic- ,
(C3-C10) -cycloaliphatic-,
(C3-C10) -cycloaliphatic (C1-C12) -aliphatic-,
(Cδ-ClO)-aryl-,
(C6-C10) -aryl- (C1-C12 ) aliphatic-,
(C3-CIO ) -heterocyclyl- ,
(C6-C10 ) -heterocyclyl- (C1-C12 ) aliphatic- ,
(C5-C10) -heteroaryl-, or
(C5-C10) -heteroaryl- (C1-C12) -aliphatic-; wherein R7 has up to 3 substituents selected independently from J2; and
J2 is halogen, -OR7, -OC (O)N(R7) 2, -N02, -CN, -CF3, -OCF3, -R7, oxo, thioxo, =NR7, =N(OR7) , 1, 2-methylenedioxy, 1,2-ethylenedioxy, -N(R7)2, -SR7, -SOR7, -S02R7, -S02N(R7)2, -S03R7, -C(0)R7, -C(0)C(0)R7, -C (0) C (0) OR7, -C(0)C(0)N(R7)2, -C(0)CH2C(0)R7, -C(S)R7, -C(S)OR7, -C(0)OR7, -OC(0)R7, -C(0)N(R7)2, -OC (O)N(R7) 2, -C(S)N(R7)2, -(CH2)0-2NHC(O)R7, -N(R7) N(R7) COR7, -N(R7)N(R7)C(0)OR7, -N(R7)N(R7)CON(R7)2, -N(R7)S02R7, -N(R7)S02N(R7)2, -N(R7)C(0)OR7, -N(R7) C (O) R7, -N(R7)C(S)R7, -N(R7)C(0)N(R7)2, -N(R7) C (S)N (R7) 2, -N(C0R7)C0R7, -N(OR7)R7, -CN, -C (=NH)N(R7) 2,
-C(0)N(OR7)R7, -C(=N0R7)R7, -OP(0)(OR7 2/ -P(O) (R7)2,
-P(0)(OR7)2, or -P(O) (H) (OR7) ; and R8 is (C1-C12) -aliphatic- (C3-C10) -cycloaliphatic-, (C6- Cl0)-aryl-, (C3-CIO) -heterocyclyl-, (C5-C10)- heteroaryl-, (C3-C10) -cycloaliphatic- (C1-C12) - aliphatic-, (C6-C10) -aryl- (C1-C12) -aliphatic-, (C3- C10) -heterocyclyl- (C1-C12) -aliphatic-, or (C5-C10)- heteroaryl (C1-C12) -aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from 0, N, N(R) , S, SO, and S02; and wherein R8 is optionally substituted with up to 6 substituents independently selected from R; comprising:
(a) reacting a compound of formula (III) :
Figure imgf000106_0001
wherein:
R9 is -N02, -C(0)0R10, -CN, R6C(0)N(H)-, R6S02N(H)-,
R6OC(0)N(H)-, (R6)2NC(0)N(H)-, R6C (0) C (0) N (H) - , R6N(H)
(R5)2NC(0)C(0)N(H)-, or R50C (0) C (O)N(H) and R2, R10 and R6 are as defined above;
with a compound of formula (X
Figure imgf000106_0002
(X) wherein Y is either a carbonyl group or an OH group; and R3, R4 and R5 are as defined above;
in the presence of coupling conditions and a solvent;
provided that if Y is an OH group, then the process further comprises (b) oxidizing the OH group to provide the compound of formula (I) ; and provided that if R9 is -N02, -C(0)OR10, or -CN, the process comprises the further step of converting the -N02, -C(0)OR10, or -CN into R6C(0)N(H)-, R6S02N(H)-, R60C(0)N(H)-, (RS)2NC(0)N(H)-, R6C (0) C (0) N (H) - , R6N(H)-, (R6)2NC(0)C(0)N(H)-, or R6OC (0) C (O)N(H) - .
ABSTRACT [0155] The present invention provides a compound of formula I :
Figure imgf000108_0001
wherein R , R , R , R , and R are as defined herein. The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated diseases and processes for preparing the compounds of the invention.
PCT/US2004/016706 2003-05-27 2004-05-27 3 - [2- (3-amino-2-oxo-2h-pyridin-1-yl) - acetylamino] - 4- oxo-pentanoic acid derivatives and their use as caspase inhibitors WO2004106304A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
NZ544156A NZ544156A (en) 2003-05-27 2004-05-27 3 - [2- (3-Amino-2-oxo-2H-pyridin-1-yl) - acetylamino] - 4- oxo- pentanoic acid derivatives and their use as caspase inhibitors
AU2004243308A AU2004243308B9 (en) 2003-05-27 2004-05-27 3 - [2- (3-amino-2-oxo-2H-pyridin-1-YL) - acetylamino] - 4- oxo-pentanoic acid derivatives and their use as caspase inhibitors
CA002526749A CA2526749A1 (en) 2003-05-27 2004-05-27 3-[2-(3-amino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
EP04753524A EP1631549A2 (en) 2003-05-27 2004-05-27 3-[2-(3-amino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
BRPI0410669-5A BRPI0410669A (en) 2003-05-27 2004-05-27 caspase inhibitors and their uses
MXPA05012837A MXPA05012837A (en) 2003-05-27 2004-05-27 Caspase inhibitors and uses thereof.
JP2006533446A JP4791365B2 (en) 2003-05-27 2004-05-27 Caspase inhibitors and their uses
CN2004800181618A CN1812972B (en) 2003-05-27 2004-05-27 Caspase inhibitors and uses thereof
IL172159A IL172159A (en) 2003-05-27 2005-11-24 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same and uses thereof
NO20056192A NO20056192L (en) 2003-05-27 2005-12-27 Capase inhibitors and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47362203P 2003-05-27 2003-05-27
US60/473,622 2003-05-27

Publications (2)

Publication Number Publication Date
WO2004106304A2 true WO2004106304A2 (en) 2004-12-09
WO2004106304A3 WO2004106304A3 (en) 2005-11-03

Family

ID=33490622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016706 WO2004106304A2 (en) 2003-05-27 2004-05-27 3 - [2- (3-amino-2-oxo-2h-pyridin-1-yl) - acetylamino] - 4- oxo-pentanoic acid derivatives and their use as caspase inhibitors

Country Status (19)

Country Link
US (2) US20040242494A1 (en)
EP (2) EP1631549A2 (en)
JP (4) JP4791365B2 (en)
KR (2) KR20110114735A (en)
CN (2) CN1812972B (en)
AR (1) AR044770A1 (en)
AU (1) AU2004243308B9 (en)
BR (1) BRPI0410669A (en)
CA (1) CA2526749A1 (en)
IL (1) IL172159A (en)
MX (1) MXPA05012837A (en)
NO (1) NO20056192L (en)
NZ (2) NZ544156A (en)
PE (1) PE20050159A1 (en)
RU (1) RU2372335C2 (en)
TW (2) TW201038534A (en)
UY (1) UY28333A1 (en)
WO (1) WO2004106304A2 (en)
ZA (1) ZA200509700B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057961A1 (en) 2004-11-24 2006-06-01 Vertex Pharmaceuticals Incorporated 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
WO2007015931A2 (en) 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
WO2008016239A1 (en) 2006-08-02 2008-02-07 Lg Life Sciences Ltd. Caspase inhibitors based on pyridazinone scaffold
WO2008056898A1 (en) * 2006-11-09 2008-05-15 Lg Life Sciences Ltd. Caspase inhibitors based on pyridazinone scaffold
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
US7960415B2 (en) 2003-05-27 2011-06-14 Vertex Pharmaceutical Incoporated Caspase inhibitors and uses thereof
EP2399916A1 (en) 2004-03-12 2011-12-28 Vertex Pharmaceuticals Incorporated Process and intermediates for the preparation of aspartic acetal caspase ihnhibitors
US9969283B2 (en) 2013-09-10 2018-05-15 General Electric Company Battery changing system and method
US9994613B2 (en) 2000-05-19 2018-06-12 Vertex Pharmaceuticals Incorporated Prodrug of an ICE inhibitor

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040350A1 (en) 2002-06-28 2005-03-30 Vertex Pharma CASPASA INHIBITORS AND USES OF THE SAME
CA2511235A1 (en) * 2002-12-20 2004-07-15 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
GB0327494D0 (en) * 2003-11-26 2003-12-31 Amersham Plc Novel imaging agents
EP1750689A1 (en) * 2004-05-15 2007-02-14 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
MX2007015419A (en) * 2005-06-08 2008-02-21 Novartis Ag Organic compounds.
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
EP2831056B1 (en) * 2012-03-31 2016-12-14 The University Of Georgia Research Foundation, Inc New anti-mycobacterial drugs against tuberculosis
EP2687511A1 (en) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinone derivatives as tissue transglutaminase inhibitors
US10143267B1 (en) 2013-12-31 2018-12-04 Dynasty Footwear, Ltd. Shoe bottom surface having attached particles
CA2948540A1 (en) 2014-05-12 2015-11-19 Conatus Pharmaceuticals Inc. Treatment of the complications of chronic liver disease with caspase inhibitors
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
JP2019500397A (en) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド Methods of using caspase inhibitors for the treatment of liver disease
AU2017339826A1 (en) 2016-10-05 2019-04-04 Novartis Ag Combination compositions comprising FXR agonists for treating or preventing a fibrotic,cirrhotic disease or disorder
MX2020012805A (en) 2018-05-29 2021-02-15 Cersci Therapeutics Inc Compounds for pain treatment, compositions comprising same, and methods of using same.
WO2020006341A1 (en) 2018-06-29 2020-01-02 Conatus Pharmaceuticals, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
US11161826B2 (en) 2019-05-10 2021-11-02 Acadia Pharmaceuticals Inc. Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
DE3261645D1 (en) 1981-02-03 1985-02-07 Airwick Ag Composition containing an abrasive substrate for the cleaning of hard surfaces
DD232699A1 (en) 1983-11-18 1986-02-05 Adw Ddr PROCESS FOR THE PREPARATION OF CHINAZOLIN-4-ON-3-ALKANSAURES AND THEIR ESTERS
FR2582514B1 (en) * 1985-05-30 1988-02-19 Rhone Poulenc Sante AMIDE DRUGS, NEW AMIDES AND THEIR PREPARATION
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
GB9216272D0 (en) 1991-08-15 1992-09-09 Ici Plc Substituted heterocycles
ES2118940T3 (en) 1992-02-21 1998-10-01 Merck & Co Inc PEPTIDIL-DERIVATIVES USEFUL AS INHIBITORS OF THE CONVERTING ENZYME OF INTERLEUKIN-1 BETA.
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
DE69532113T2 (en) 1994-03-31 2004-07-29 Vertex Pharmaceuticals Inc., Cambridge PYRIMIDINE DERIVATIVES AS INTERLEUKIN INHIBITORS
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
CN1131210C (en) * 1995-04-27 2003-12-17 三菱制药株式会社 Heterocyclic amide compounds and medicinal use of the same
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US6063794A (en) * 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
JP2001508404A (en) 1996-10-11 2001-06-26 ワーナー―ランバート・コンパニー Sulfonamide interleukin-1β converting enzyme inhibitor
AU738341B2 (en) * 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
WO1998018781A2 (en) 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
BR0009610A (en) * 1999-04-09 2002-02-13 Cytovia Inc Caspase inhibitors and their use
DK1176956T3 (en) 1999-05-07 2008-05-26 Encysive Pharmaceuticals Inc Carboxylic acid derivatives which inhibit the binding of integrins to their receptors
IL146312A0 (en) 1999-05-07 2002-07-25 Texas Biotechnology Corp Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (en) * 1999-12-08 2003-02-26 Vertex Pharma A CASPASE INHIBITING COMPOUND, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, A METHOD FOR THE SYNTHESIS OF THE SAME AND AN INTERMEDIATE COMPOUND PARADICHA SYNTHESIS
DE60131160T2 (en) 2000-06-07 2008-08-07 Vertex Pharmaceuticals Inc., Cambridge CASPASE INHIBITORS AND ITS USES
WO2003024955A2 (en) * 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AU2002348533A1 (en) 2001-10-09 2003-05-26 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
AU2003211052A1 (en) 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
AU2003225088A1 (en) * 2002-04-19 2003-11-03 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
AR040350A1 (en) * 2002-06-28 2005-03-30 Vertex Pharma CASPASA INHIBITORS AND USES OF THE SAME
CA2511235A1 (en) 2002-12-20 2004-07-15 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (en) 2003-05-27 2005-04-19 Vertex Pharma DERIVATIVES OF 3- [2- (3-AMINO-2-OXO-2H-PYRIDIN-1-IL) -ACETILAMINO] -4-OXO-PENTANOICO AS CASPASE INHIBITORS
ATE543803T1 (en) * 2004-11-24 2012-02-15 Vertex Pharma 3-Ä2-(3-AZYLAMINO-2-OXO-2H-PYRIDINE-1-YL)ACETYLAMINOÜ-4-OXOPENTANIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS
JP2009502922A (en) 2005-07-28 2009-01-29 バーテックス ファーマシューティカルズ インコーポレイテッド Caspase inhibitor prodrug

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARCIA-CALVO ET AL., J. BIOL. CHEM., vol. 273, 1998, pages 32608 - 32613
ROGERS ET AL., BRAIN RES. BULLETIN, vol. 44, 1997, pages 131
THORNBERRY ET AL., BIOCHEMISTRY, vol. 33, 1994, pages 3943 - 3939

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994613B2 (en) 2000-05-19 2018-06-12 Vertex Pharmaceuticals Incorporated Prodrug of an ICE inhibitor
US7960415B2 (en) 2003-05-27 2011-06-14 Vertex Pharmaceutical Incoporated Caspase inhibitors and uses thereof
EP2399915A1 (en) 2004-03-12 2011-12-28 Vertex Pharmaceuticals Incorporated Process and intermediates for the preparation of aspartic acetal caspase inhibitors
EP2399916A1 (en) 2004-03-12 2011-12-28 Vertex Pharmaceuticals Incorporated Process and intermediates for the preparation of aspartic acetal caspase ihnhibitors
US8362043B2 (en) 2004-11-24 2013-01-29 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2006057961A1 (en) 2004-11-24 2006-06-01 Vertex Pharmaceuticals Incorporated 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
WO2007015931A2 (en) 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
WO2007015931A3 (en) * 2005-07-28 2007-06-07 Vertex Pharma Caspase inhibitor prodrugs
JP2009502922A (en) * 2005-07-28 2009-01-29 バーテックス ファーマシューティカルズ インコーポレイテッド Caspase inhibitor prodrug
US8168798B2 (en) 2005-07-28 2012-05-01 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
EP2046757A1 (en) * 2006-08-02 2009-04-15 LG Life Sciences Ltd. Caspase inhibitors based on pyridazinone scaffold
EP2046757A4 (en) * 2006-08-02 2011-04-27 Lg Life Sciences Ltd Caspase inhibitors based on pyridazinone scaffold
JP2009545585A (en) * 2006-08-02 2009-12-24 エルジー・ライフ・サイエンシーズ・リミテッド Caspase inhibitor containing pyridazinone structure
US8481537B2 (en) 2006-08-02 2013-07-09 Lg Life Sciences Ltd. Caspase inhibitors based of pyridazinone scaffold
WO2008016239A1 (en) 2006-08-02 2008-02-07 Lg Life Sciences Ltd. Caspase inhibitors based on pyridazinone scaffold
WO2008056898A1 (en) * 2006-11-09 2008-05-15 Lg Life Sciences Ltd. Caspase inhibitors based on pyridazinone scaffold
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
US9969283B2 (en) 2013-09-10 2018-05-15 General Electric Company Battery changing system and method

Also Published As

Publication number Publication date
WO2004106304A3 (en) 2005-11-03
RU2372335C2 (en) 2009-11-10
BRPI0410669A (en) 2006-06-20
JP4791365B2 (en) 2011-10-12
CA2526749A1 (en) 2004-12-09
TWI344956B (en) 2011-07-11
KR20110114735A (en) 2011-10-19
TW201038534A (en) 2010-11-01
EP1631549A2 (en) 2006-03-08
ZA200509700B (en) 2007-03-28
US20090093416A1 (en) 2009-04-09
IL172159A (en) 2012-03-29
KR20060015626A (en) 2006-02-17
JP2007506803A (en) 2007-03-22
CN101775012A (en) 2010-07-14
AR044770A1 (en) 2005-10-05
AU2004243308B2 (en) 2011-09-29
CN1812972A (en) 2006-08-02
EP2412707A2 (en) 2012-02-01
NZ544156A (en) 2009-05-31
PE20050159A1 (en) 2005-04-19
NO20056192L (en) 2005-12-27
NZ575857A (en) 2010-11-26
TW200510317A (en) 2005-03-16
US20040242494A1 (en) 2004-12-02
AU2004243308A1 (en) 2004-12-09
UY28333A1 (en) 2004-12-31
AU2004243308B9 (en) 2012-02-09
IL172159A0 (en) 2006-04-10
RU2005140657A (en) 2006-06-10
EP2412707A3 (en) 2012-06-13
JP2012036206A (en) 2012-02-23
CN1812972B (en) 2010-04-28
JP2012021019A (en) 2012-02-02
JP2007308501A (en) 2007-11-29
MXPA05012837A (en) 2006-02-13
US7960415B2 (en) 2011-06-14

Similar Documents

Publication Publication Date Title
US7960415B2 (en) Caspase inhibitors and uses thereof
EP1833794B1 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
JP2007506803A5 (en)
JP2008521809A5 (en)
JP2004509120A (en) Caspase inhibitors and their uses
NZ519424A (en) Caspase inhibitors and uses thereof
US7612091B2 (en) Caspase inhibitors and uses thereof
JP2002526533A (en) Phenylalkanoic acid derivatives as alpha4 integrin inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2526749

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 172159

Country of ref document: IL

Ref document number: 2006533446

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/012837

Country of ref document: MX

Ref document number: 1020057022598

Country of ref document: KR

Ref document number: 2004753524

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005/09700

Country of ref document: ZA

Ref document number: 200509700

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004243308

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2589/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 544156

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004243308

Country of ref document: AU

Date of ref document: 20040527

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004243308

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048181618

Country of ref document: CN

Ref document number: 2005140657

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020057022598

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004753524

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0410669

Country of ref document: BR